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Summary 
The Adeno-associated virus (AAV) presents itself as an attractive vector for gene therapy due 
to its broad tissue tropism, ease of manipulation and lack of pathogenicity. So far, three FDA 
approved AAV-based gene therapies are available, with more than 100 ongoing clinical trials. 
However, aspects of the AAV life cycle still limit its transduction capacities such as receptor 
binding, intracellular trafficking, uncoating, single-strand to double strand conversion and 
interaction with host cell factors. Although technologies have been developed to tackle most 
of these challenges, there is still a gap in knowledge on the restriction through the interaction 
with host cell factors. Bridging this gap in AAV biology shall additionally enable the 
generation of more efficient gene therapy vectors. In this study, the restriction of AAV 
through the ubiquitin-proteasome system was evaluated. The speckled-type POZ protein 
(SPOP) is a member of the E3-ubiquitin ligase complex with Cullin 3. Both Cullin 3 and SPOP 
were previously identified though a tandem-affinity purification as putative interaction 
partners of AAV capsid protein VP1. In addition, a yeast 2 hybrid screen also confirmed the 
interaction with SPOP. In this study, CRISPR-Cas9 technology was employed to knockout 
SPOP and Cullin 3; and evaluate their effects on AAV. SPOP was found to restrict AAV in both 
parts of the life cycle. During entry, SPOP had a 2-fold effect on AAV transduction and 
regulated the turnover of capsids (up to 3 fold more capsids were seen in the absence of 
SPOP). However, an increase of transduction through proteasome inhibition in the SPOP 
knockout cells indicated that it was not the sole E3 ubiquitin ligase complex involved in the 
restriction of AAV transduction. After de novo synthesis of capsid proteins, SPOP was able to 
regulate the turnover of both assembled capsids and unassembled capsid proteins. The latter 
could be visualized as distinct VP clusters in the nuclei of SPOP knockout cells. A restoration 
of SPOP in the knockout cells was able to destabilize the capsid proteins but wash not able to 
reach the levels seen in the parental condition, although the functionality of restored SPOP 
could not be confirmed as other endogenous SPOP substrates showed variable patterns. 
Proteasome inhibition was able to stabilize unassembled capsid proteins to comparable 
levels as the absence of SPOP but had no additive effect upon combination. Cullin 3 did not 
have a significant effect in either part of the AAV life cycle. The results of this study provide 
more concrete information about the involvement of the ubiquitin-proteasome system in the 
restriction of AAV.  
 
 
 
 
 
 
 
Zusammenfassung 
Das Adeno-assoziierte Virus (AAV) stellt aufgrund seines breiten Gewebetropismus, seiner 
einfachen Handhabung und seiner geringen Pathogenität einen attraktiven Vektor für die 
Gentherapie dar. Bislang gibt es drei von der FDA zugelassene AAV-basierte Gentherapien, 
mit mehr als 100 laufenden klinischen Studien. Jedoch schränken manche Aspekte des AAV-
Lebenszyklus, wie Rezeptorbindung, intrazellulärer Transport, Entpacken, Einzelstrang-zu-
Doppelstrangkonvertierung und die Interaktion mit Wirtszellfaktoren immer noch die 
Anwendung ein. Obwohl Technologien entwickelt wurden, um die meisten dieser 
Herausforderungen zu bewältigen, gibt es immer noch eine Wissenslücke bezüglich der 
Interaktion von AAV mit Wirtszellenfaktoren. Das Schließen dieser Lücke soll   die 
Entwicklung effizienterer Gentherapievektoren ermöglichen. In dieser Studie wurde die 
Inhibition von AAV durch das Ubiquitin-Proteasom-System untersucht. Das Speckle-type 
POZ-Protein (SPOP) ist zusammen mit Cullin 3 ein Mitglied eines E3-Ubiquitin-
Ligasekomplexes. Sowohl Cullin 3 als auch SPOP wurden in voran gegangenen Studien durch 
eine Tandem-Affinitätsaufreinigung als mutmaßliche Interaktionspartner des AAV-
Kapsidproteins VP1 identifiziert. Darüber hinaus bestätigte ein yeast-two-hybrid screen 
ebenfalls die Interaktion  von VP1 und SPOP. In dieser Studie wurde die CRISPR-Cas9 
Technologie eingesetzt, um einen knockout von SPOP und Cullin 3 zu erreichen und deren 
Auswirkungen auf AAV zu bewerten. Es wurde festgestellt, dass SPOP in frühen und späten 
Phasen des  Lebenszyklus AAV inhibiert. Während der Transduktion zeigt SPOP einen 2-
fachen Effekt auf die AAV Transduktion und reguliert den Abbau von Kapsiden (in 
Abwesenheit von SPOP wurden bis zu 3-fach mehr Kapside nachgewiesen). Ein Anstieg der 
Transduktion durch eine Proteasom Inhibition in den SPOP-knockout-Zellen zeigte jedoch, 
dass neben SPOP auch andere E3-Ubiquitin-Ligasen  an der Hemmung der AAV-Transduktion 
beteiligt sind. Nach der Translation der Kapsidproteine konnte SPOP sowohl den Umsatz der 
assemblierten Kapside als auch der nicht-assemblierten Kapsidproteine regulieren. Letztere 
konnten als deutliche VP-Akkumulationen in den Kernen von SPOP-knockout-Zellen 
visualisiert werden. Eine Rekonstitution von SPOP in den knockout-Zellen konnte den Effekt, 
der im ursprünglichen Zustand zu beobachten war, nicht umkehren, mit der Einschränkung, 
dass die vollständige Wiederherstellung der Funktionalität von SPOP  mittels Analyse von 
bekannten SPOP Substraten nicht bestätigt werden konnte. Die Proteasom-Hemmung war in 
der Lage, nicht-assemblierte Kapsidproteine auf vergleichbare Niveaus wie das Fehlen von 
SPOP zu stabilisieren, aber kein additiver Effekt bei der Kombination. Cullin 3 hatte in keinem 
der beiden Teilen des AAV-Lebenszyklus einen signifikanten Effekt.  Die Ergebnisse dieser 
Studie liefern konkretere Informationen über die Beteiligung des Ubiquitin-
Proteasomsystems an der Hemmung von AAV zu unterschiedlichen Phasen des viralen 
Lebenszyklus. 
 iii 
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1 Introduction  
1.1 Adeno-associated virus history and biology 
In 1965, a novel parvovirus was discovered as a contaminant of a simian adenovirus type 15 
culture, the scientists proceeded to name an ‘adeno-associated virus’. The initial tests showed 
that the virus was incapable of self-replication, needing the adenovirus to do so. The first 
experiments also eluded to its non-pathogenic nature both in vitro when several tissue types 
were inoculated and in vivo when newborn mice and hamsters were infected via different 
routes [1]. From that point immense amounts of research have gone into the study, 
classification and application of the virus.  
 
It was taxonomically classified under the sub-family of dependoparvovirus due to its inability 
to enter the lytic cycle without the presence of a helper virus, later herpesviruses, vaccinia 
and HPV were also identified as helper viruses [2], [3]. In the absence of a helper virus, AAV 
was found to enter a latent state by integrating into the host genome [4]. The biphasic life 
cycle character of the virus along with its inability to cause disease, presented its potential 
for development as a gene therapy vector.  
 
Thirteen different serotypes and 108 isolates from human/non-human primates, have been 
discovered to date and AAV2 is the best studied serovar [5]–[7]. The serotypes share varying 
levels of homology, for example AAV2, 3 and 6 share 85% homology of rep ORF and 80% of 
cap ORF sequences; while AAV5- which is considered the most unique serotype, only sharing 
54.5% sequence homology of rep sequences [8], [9]. These differences are thought to confer 
the specific tissue tropism seen among the serotypes, which can be exploited when targeting 
different organs/cell types (Table 1.1).  
 
The serotypes also utilize different cellular receptors and co-receptors. The adeno-associated 
virus receptor (AAVR) has been recently identified as the main receptor for most serotypes, 
except AAV4 which is independent and AAV5 which shows only partial dependence on AAVR 
[10], [11]. Other receptors implicated in the attachment of AAV include- the heparan sulfate 
proteoglycan (HSPG) for AAV2 and 3, O-linked sialic acid for AAV4, the platelet-derived 
growth factor receptor (PDGF-R) for AAV5 and a 37/67-kilodalton laminin receptor for 
AAV8, 2, 3, and 9[12]–[18]. 
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Table 1.1 Tissues transduced by the different AAV serotypes [19] 
Tissue Serotype  
Kidney AAV2 
Lung  AAV4, AAV5, AAV6, AAV9 
CNS  AAV1, AAV2, AAV4, AAV5, AAV8, AAV9 
RPE (Retinal Pigment Epithelium)  AAV1, AAV2, AAV4, AAV5, AAV8 
Photoreceptor Cells  AAV2, AAV5, AAV8 
Liver AAV7, AAV8, AAV9 
Pancreas  AAV8 
Skeletal Muscle  AAV1, AAV6, AAV7, AAV8, AAV9 
Heart  AAV1, AAV8, AAV9 
 
1.1.1 The genome structure of the Adeno-associated virus 
AAV has a linear, single stranded, 4.7kb DNA genome that encodes for inverted terminal 
repeats (ITRs) that flank the three genes: rep, cap and AAP (Figure 1.1) [20]–[23]. The ITRs 
are 145-bp palindromic, cis-acting hairpin structures that act as primers for AAV replication 
[24]. In the 1980s, when initial efforts to develop AAV as a gene therapy vector began, which 
included the successful virus production from a plasmid construct, Samulski and colleagues 
found that the ITRs were the most essential part of the genome, as 96% of the sequences 
could be replaced by a transgene but the ITRs (which make up 4%) were essential for 
replication [25]. The other genes act in trans and are further described below. 
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Figure 1.1 Adeno-associated type 2 genome organization. Adeno-associated type 2 
genome organization (Adapted from Galibert and Merten, 2011 [26]). The hairpin 
structures on either side are the ITRs and all transcripts have a poly-adenylation signal 
present at position 96. The left ORF encodes for the Rep proteins (Rep 78, Rep 68, Rep 52, 
Rep 40- in red) which are driven by the p5 and p19 promotors with alternative splicing. The 
right ORF encodes for capsid proteins (VP1, VP2 and VP3-blue) from two transcripts via 
alternative splicing and the assembly activating protein (AAP-orange) which is located on a 
separate ORF; and arise from the p40 promotor. Other serotypes show a similar organization. 
ORF- Open Reading Frame. 
1.1.1.1 The Replication Proteins (rep)  
The function of the left side of the genome was not known initially, however a replication 
function was assumed. Four non-structural Rep proteins were identified: Rep78, Rep68, 
Rep52 and Rep40-the number denotes the molecular weights- all possessing ATPase and 
helicase activity. Rep 78 and Rep 68 are alternative splice products driven by the P5 
promoter and have regulatory roles throughout the AAV life cycle. They are required for DNA 
replication and regulate the expression of AAV genes in a positive or negative manner 
depending on the presence or absence of a helper virus, respectively [27]. The smaller Rep 
proteins-Rep52 and Rep40- are alternative splice products driven by P19 promotor, involved 
transcriptional regulation and in viral packaging- by accumulating the single stranded AAV 
DNA which is thereafter packaged into capsids (Figure 1.1) [28], [29]. 
 
The q arm of chromosome 19 was found to contain Rep binding elements, dubbed the AAVS1 
site. During the latent natural infection, the Rep proteins facilitate the site-specific 
integration of AAV [30]. Rep52 and Rep78 have also been recently shown to act in the rescue 
from latency [31]. 
 
1.1.1.2 The Capsid Proteins (cap) 
The right side of the genome encodes for the viral capsid proteins VP1, VP2 and VP3 and the 
assembly activating protein (AAP) on a separate ORF (Figure 1.1). The viral capsid proteins 
are driven by the p40 promoter and share the same C-terminus but have varying N-termini 
due to alternative splicing. VP1 is a 87kDa unspliced variant that has a N-terminal unique 
region that contains a PLA-2 domain which is critical for viral infectivity by facilitating 
endosomal escape and nuclear entry [32], [33]. It has also been recently shown to have 
protease activity [34]. VP2 and VP3 are both translated from the more abundant major 
spliced mRNA transcript, but due to the non-canonical ACG start codon on VP2, it is translated 
less efficiently producing a 72kDa protein [35]. VP2 is considered non-essential, as ΔVP2 
capsids were still infectious [36]. VP3 is the most abundant protein, with a molecular weight 
of 62kDa. When expressed alone it can form capsids in some serotypes but otherwise 
requires the expression of AAP [37], [38].  
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1.1.1.3 The Assembly-Activating Protein (AAP)  
AAP is encoded on a separate ORF, overlapping with the cap ORF (Figure 1.1). It is transcribed 
through a non-canonical CTG start codon and encodes a 23kDa protein [23]. It shows high 
homology among the different serotypes and is essential for the capsid assembly of most 
types [37]. However, it has been found to be non-essential only for AAV4, 5 and 11 [38]. AAP 
is thought to act as a scaffold for newly synthesized capsids to assemble. It is located in the 
nucleolus for AAV2 but in other nuclear bodies for the other serotypes [38], [39]. 
 
1.1.2 The organization of the AAV Capsid  
The AAV capsid proteins are expressed in a molar ratio of 1:1:10, resulting in 60 subunits- 5 
VP1, 5 VP 2 and 50 VP3- that assemble to form a ~25nm icosahedral capsid with T=1 
symmetry [40]. VP3 is contained in all three proteins, and VP2 is part of VP1, but VP1 has a 
unique N-terminus (VP1u) with an extra 137 amino acids. The VP1u domain is hidden within 
the capsid and becomes exposed during virus entry. This has been demonstrated in vitro 
upon heat treatment and thought to act in a similar manner once it enters the endosomes, 
due to its low pH and the concerted actions of cathepsin B and L [41], [42]. 
The structure of the monomeric subunit is a conserved β-barrel core. The outer surface of 
the capsid is composed of long intrastrand loop insertions-named according to where they 
flank, with β-ribbons and other secondary structural elements. The longest interstrand loop 
is the GH loop and the extensive interaction between 3 VP proteins at the 3-fold symmetry 
axis results in a spike. At the 5-fold symmetry axis, a cylindrical structure is formed by an 
antiparallel β-ribbon from 5 DE-loops each, forming a canyon. A depression (dimple) is found 
at the 2-fold axis. The peaks and valleys of the 3-fold axis have been linked to the high 
variability between the G-H β-strands (Figure 1.2). The variable regions are thought to 
moderate interactions with different cellular receptors and antibodies [43].  
 
 
 
Figure 1.2 The adeno-associated virus 1 
capsid (adapted from Tseng and Mckenna, 
2014[44]) Heat map of the ~110–130 Å AAV1 
capsid-from centre to surface. The capsid is 
composed of 60 monomers of VP. The features 
and 2-,3- and 5- fold axes are displayed.  
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1.1.3 The life cycle of Adeno associated virus  
AAV2 is the best studied AAV serotype, with numerous studies about its life cycle as a model 
for the other serotypes (Figure 2.3). AAVs commonly attach to glycans as the primary 
receptor, the heparin sulfate proteoglycan (HSPG) was identified as the main receptor of 
AAV2 and 3[15], [17]. N-linked galactose for AAV9 and O- and N-linked sialic acid moieties 
for AAV1, 4, 5 and 6 [45]–[48]. No glycan receptors have been identified for AAV7, 8 and 10-
12 so far. Apart from the glycans, different proteinaceous receptors have been examined as 
co-receptors that aid entry. For AAV2 these are aVβ5 integrin, CD9 tetraspanin, fibroblast 
growth factor receptor-1 (FGFR1) and hepatocyte growth factor receptor (c-MET) [13], [14], 
[49], [50]. For the other serotypes, several co-receptors have been named, the most wide-
spanning are the laminin receptor (LamR) aids entry of AAV2, 3, 8, and 9; and the recently 
discovered adeno-associated virus receptor (AAVR) is involved in the entry of AAV1, 2, 3B, 5, 
6, 8 and 9 [10], [12].  
 
After receptor attachment the AAV particles are internalized into endosomes. There is 
evidence that this occurs through the action of the GPI-enriched endocytic compartment 
(CLIC/GEEC), micropinocytosis, caveolar endocytosis, or through clathrin-mediated 
endocytosis pathways. Although most of particles do not culminate in productive 
transduction, and different routes have shown differing efficiencies [51]–[53]. In the 
endosomes, the low pH and the actions of cathepsin B and L play a role in triggering a 
conformational change that triggers the exposure of the VP1 N-terminus from the capsid [41], 
[42], [54]. The VP1u region contains the PLA2 domain which is required for the escape from 
endosomes [55]–[59]. The virus relies on the host cell machinery for trafficking to the 
nucleus via the network of microtubules and through the trans-golgi network (Figure 2.3) 
[60], [61].  
 
Two of the three short basic amino acid sequence elements (basic clusters [BCs]) in the 
VP1/2 common region contain a non-classical nuclear localization signal (NLS) that 
facilitates the entry of the capsids [59]. Once in the nucleus, AAV2 particles are readily 
transported into the nucleolus before they reenter the nucleoplasm. The exact reason for this 
sequestration is unknown especially given that the siRNA knockdown of nucleolar factors 
increases transduction up to 15-fold and together with hydroxyurea has an additive effect up 
to 50-fold. Nevertheless, this sequestration is thought to permit uncoating and gene 
transduction [62]. After egress into the nucleoplasm the capsids undergo uncoating, however 
it is also believed that full disassembly of the capsids is not required for the release of the 
genome as proven with other autonomous parvoviruses [63], [64]. The kinetics of the release 
of the DNA depends on the serotype and the cells being transduced [65], [66]. 
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Figure 1.3 AAV life cycle (Adapted from Daya and Berns, 2008; Pillay and Carette,2017 [67], 
[68]).  AAV approaches the cell surface and interacts with its AAVR and HSPG receptors. It 
becomes internalized and undergoes conformational changes to allow it to escape the 
endosome and traffic through the intracellular network before release into the cytoplasm 
and into the nucleus where it uncoats. At this point it can enter either the lytic or latent phase. 
In the presence of a helper virus it undergoes replication, gene expression, packaging and 
release. In the absence of a helper virus it either undergoes site-specific integration into 
AAVS1 on chromosome 19 or is retained in episomes. Super infection with a helper virus (or 
cellular stress) can rescue the virus from latency. All stages of the life cycle involve complex 
interactions between the AAV genome, the proteins it produces, the helper virus and the host 
cell machinery.  
 
The viral DNA is released but is in a transcriptionally inactive state. From here it can enter 
either the lytic or latent phase. In the lytic phase, helper virus genes are expressed aiding AAV 
gene expression. For adenovirus these are E2a, E4 and VA RNA, while other helper viruses 
act in different means [69]. The single stranded (ss) DNA is then transformed into double 
stranded (ds) DNA through either the ligation of plus and minus DNA strands via a co-
infection in the same cell or de novo synthesis of the second DNA strand using the 3' hydroxyl 
group of the ITR as a primer and relying on the host cell polymerases. The larger rep proteins- 
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Rep68 and Rep78 play a specific role in catalyzing endonucleolytic cleavage at the terminal 
resolution site (trs) in a strand-specific manner. The single strand to double strand 
conversion is considered a rate-limiting step of transduction [70]–[73]. The smaller rep 
proteins-Rep40 and Rep52 play a role in generating and accumulating ss-viral genomes from 
ds-replicative intermediates [74].  
 
Transcription and translation of the AAV genome is regulated by helper virus factors. Firstly 
the Rep proteins are produced, due to their regulatory role on other parts of the life cycle 
then the capsid proteins (VP1, 2 and 3) and AAP are produced [75]–[77]. The assembly-
activating protein is thought to act as a scaffold for capsid assembly in the nucleolus [23]. The 
newly synthesized DNA is then inserted into the pre-formed capsids through the 5-fold 
symmetry axis, by the helicase activity of the small rep proteins [78], [79]. The helper virus 
then aids the release of newly synthesized capsids [80].  
 
In the absence of a helper virus the AAV genome can remain episomally (in the case of AAV 
vectors) or be integrated into the host genome. For the latter, the concerted actions of Rep 
68, Rep 78 and the ITRs direct the integration into the long q arm of human 19 chromosome, 
19q13.3-qter (AAVS1) [81], [82]. The virus can re-enter the lytic phase by super-infection or 
induction of cellular stress [83]. 
 
1.1.4 The engineering of Adeno associated virus vectors 
AAVs simple biology, its non-pathogenic nature and ability to establish latency were the 
original factors that drove the engineering of the virus for gene therapy [1]. Coupled to the 
subsequent finding that the ITRs worked in cis, and were the only sequences required to drive 
replication, packaging and genome rescue of the transgene of interest [25]. This allowed for 
the rep and cap to be supplied in trans together with the co-infection of a helper virus in order 
to drive the synthesis of the transgene and have it inserted into AAV capsids. When the helper 
virus genes critical to AAV were identified, they were subsequently cloned into a plasmid and 
provided in trans eliminating the need for helper virus co-infection [84]–[86]. The next issue 
was how to scale-up transfections, as high vector titers were needed for use in animal 
experiments and clinical trials, thus efforts were put into producing cell lines with stable rep 
and cap expression to allow the production with high vector yields [87]–[89]. The 
baculovirus-insect cell system was  also developed as an transfection-alternative, scale up 
method [90]. Insights in receptor usage have also allowed for the development of new 
purification technologies by affinity chromatography and ion-exchange chromatography, 
which can also be readily scaled-up [91]–[93]. 
 
Since the capsid structure determines tissue and cell specificity through the interaction with 
various cellular receptors and host cell proteins during transduction, huge amounts of efforts 
have been put into modifying the capsids. This strategy could be used to engineer capsids to 
Introduction 
 
8 
 
target specific tissues/cells of interest, but also has the additional benefit of delivering 
transgenes without immune activation caused by previous exposure- either through original 
vector administration or natural infection. These include immunological, genetic or chemical 
modifications. One approach is by using capsid sequences from non-human AAVs [94], [95]. 
Directed evolution via high-throughput screening methods and AAV capsid libraries, with in 
vivo selection has also been used to identify the best capsid variants for different cell types 
[96]–[98]. 
 
A big limitation of AAV is the 4.7kb genome capacity. To circumvent this issue various 
developments have been made such as dual AAV vectors. This involves the co-transduction 
of two halves of a larger gene, allowing for reassembly either through intermolecular 
recombination mediated by the ITRs that forms concatamers (dual trans-splicing vectors; 
homologous recombination of the 5’ and 3’ genomes (dual AAV overlapping vectors) or a 
combination of both mechanisms (dual AAV hybrid vectors) [99]–[102]. In vivo, dual vectors 
produce full-length proteins and show therapeutic efficiency, but require high vector doses 
[102]. Another approach includes protein transplicing, whereby separate protein 
domains/polypeptides are encoded in two different expression cassettes. Upon AAV vector 
administration the polypeptides are produced independently and re-assemble to form a full 
length protein [103], [104]. 
 
The single strand to double strand conversion presents another bottleneck in AAV infection. 
Self-complementary AAV vectors (scAAV) eliminate the rate limiting step, by unfolding into 
double stranded DNA, and initiating replication and transcription directly [105]. scAAVs have 
been successfully developed into gene therapy vectors that have been used in clinical trials 
to treat Hemophilia B and spinal muscular atrophy [106], [107]. 
 
Continual vector optimization combined with a deeper understanding of AAV biology has led 
to the better AAV vector-based therapies against several different gene-deficiencies. This has 
resulted in over 100 clinical trials and the successful EMA and FDA approval of 2-3 therapies 
against Leber’s congenital disease (Luxturna), lipoprotein lipase deficiency (Glybera) and 
spinal muscular atrophy (Zolgensma-pending EU approval) [108]–[111]. That 
notwithstanding, some open issues in developing better vectors remain such as AAV vector 
immunogenicity and persistence. These challenges can be tackled by developing new 
technologies, but also by also filling the gaps of knowledge that remain open in the AAV life 
cycle such as the consequence of interactions with different cellular host factors.  
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1.2 The Ubiquitin-Proteasome System (UPS) 
The UPS is a means of quality control, playing a role in various cellular processes including- 
histone modification, DNA repair, cell cycle progression and in the pathogenesis of various 
diseases. The UPS exists both in the nucleus and the cytoplasm of cells [112]. It involves the 
addition of a 76 amino acid (~8 kDa) ubiquitin tag -that is conserved in all eukaryotes- to 
targeted substrates, via a cascade of three enzymes (Figure 1.4a). The process of protein 
ubiquitination begins with the activation of a conserved glycine residue on the C-terminus of 
ubiquitin, which is catalyzed by E1, a ubiquitin-activating enzyme (n ≥ 2 in humans). PPi is 
displaced from ATP to form the ubiquitin adenylate intermediate which is transferred to E1 
at its thiol site, releasing AMP. Thereafter the ubiquitin is transferred to the thiol site of the 
E2- ubiquitin-conjugating enzyme (n > 50). In the final step E3, a ubiquitin ligase (n > 500 in 
humans) facilitates the transfer of ubiquitin to a lysine residue on the target protein through 
an isopeptide linkage [113].  
 
The different combinations of E2 and E3 regulate the biological specificity of the process. The 
addition of poly-ubiquitin to Lys48 or branched Lys48-Lys11 chains signal for proteasomal 
degradation while monoubiquitination facilitates non-proteolytic functions such as altering 
the localization or activity of a protein. There are three major families of E3 enzymes based 
on the functional class of substrates they interact with, similarities in structure and 
mechanism in which they transfer ubiquitin; namely: Really Interesting New Gene (RING), 
Homologous to E6AP C-terminus (HECT), and RING-between-RING (RBR) domain-
containing E3 ligase families [114]–[121]. RING E3 ligases bind both the E2 enzyme and the 
substrate catalysing the ubiquitin transfer in a direct manner [122]. Contrastingly, the 
activated ubiquitin is transferred from the E2 enzyme to a cysteine residue in the HECT E3 
enzyme before it is conjugated to the substrate [123]. The RBR E3 ligases share similarity 
with RING E3s in that they contain 2 RINGs linked via an in-between-RING (IBR) domain, but 
the mode of action is similar to HECT E3s, in that the activated ubiquitin is first transferred 
to the E3 then to the substrate (Figure1.4a) [124], [125]. 
 
Deubiquitnating enzymes (DUBs) can edit or completely remove conjugated ubiquitin from 
the proteins of interest. They are important in modifying the fate of substrates and can 
disassemble poly-ubiquitin chains in order to recycle the ubiquitin monomers (Figure 1.4b) 
(see [126] for review).  
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Figure 1.4 The UPS system and deubiquitination (adapted from Zheng et al., 2016 [127]) 
 a. Ubiquitination- Ubiquitin is attached to a cysteine residue of ubiquitin activating enzyme- 
E1, 10 catalyzed by ATP, then transferred to the active site cysteine of the ubiquitin-
conjugating enzyme- E2. E2 thereafter transfers the ubiquitin to the lysine residue on the 
substrate through a specific E3 enzyme. For E3 RING ligases, the ubiquitin is transferred 
directly from E2 to the substrate. While for HECT and RBR E3 ligases, the ubiquitin is initially 
conjugated to a cysteine residue in the E3 enzyme before transfer to the substrate, resulting 
in different ubiquitin linkages that serve other purposes. 
 b. Deubiquitination- Deubiquitinating enzymes (DUBs) edit and/or reverse ubiquitination 
of substrates, thus determining their cellular fate. DUBs can modify the type or length of 
polyubiquitin chains and can disassemble ubiquitins attached in order to recycle the 
ubiquitin monomers. PPi, inorganic pyrophosphate. 
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1.2.1 The Cullin-RING 3 Ubiquitin ligase complex 
 The Cullin-RING ubiquitin ligases (CRLs) are the most common E3 ligases to date. They form 
multimeric complexes based on a cullin scaffold with a catalytic center and are highly 
conserved among different species [128], [129]. Eight different cullins have been classified 
in mammals (Cul1, 2, 3, 4A, 4B, 5, 7 and 9/PARC). Each CRL complex is composed of different 
adaptors and/or substrate recognition subunits (srs) (Table 1.2). All CRLs act by bringing the 
substrate into close proximity to the E2-conjugating enzyme, thus facilitating the transfer of 
activated ubiquitin to the substrate [130]. Nedd8 acts as a modulator of CRL activation by 
triggering a conformational change at the carboxy-terminal domain (closed form) that 
results in the freeing of the RING domain (open active form) [131]. 
 
Table 1.2 CRL complex components and adaptors[132] 
Cullin E3 complex components Adapter 
1 Skp1-Cul1-F-box-Rbx1 Skp1 
2 Elongin BC-Cul2-Protein SOCS-Rbx1 ElonginC/ElonginB 
3 BTB-Cul3-Rbx1 Protein - 
4A, 4B DDB1-Cul4A/4B-DDB2 o CSA-Rbx1 DDB1 
5 Elongin BC-Cul5-Protein SOCS-Rbx1 ElonginC/ElonginB 
7 Skp1-Cul7-Fbx29-Rbx1 Skp1 
9/PARC ?-Cul9-Rbx1 ? 
Skp1: S-phase kinase-associated protein 1; F-box: motif that acts as a site of protein–protein 
interaction; Rbx1: RING-box protein (also known as ROC1); BTB: bric-a-
brac/tramtrack/broad-complex; DDB1: damage-specific DNA binding protein 1; SOCS: 
suppressors of cytokine signalling protein; CSA: cockayne syndrome group A protein. 
 
The Cullin 3 Ubiquitin ligase complex (CRL3) differs from other CRLs because it does not 
employ an adaptor protein but instead recognizes proteins with a bric-a-brac, tram-track and 
broad complex (BTB) domain that binds at the Cul3 N-terminus [133], [134]. The BTB 
domain was originally discovered in Drosophila melanogaster transcription factors, but since 
then over 200 BTB proteins have been found encoded in the human genome [135], [136]. The 
BTB-containing proteins serve as substrate recognition subunits (srs) to facilitate substrate 
binding and have different domains that facilitate the recognition of an array of substrates 
including – Kelch, Zinc finger, Ras and MATH domains[137]. The RING-domain protein 
(Rbx1) binds to the C-terminus and facilitates the recruitment of the E2-conjugating enzyme 
[138], [139].  
 
The CRL3 complex plays important roles in regulating key cellular processes including cell 
migration, oxidative stress, retrograde trafficking and cell cycle progression [140]–[144].  
The absence of Cul3 has been demonstrated to inhibit cell migration in drosophila and human 
cells, via the stabilization of RhoA, a Cul3 substrate, that controls stress fiber development in 
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the actin cytoskeleton [144]. The absence of Cul3 also causes embryonic lethality in mice, 
thus highlighting its critical role in the cell [145]. A well-studied substrate recognition 
subunit of CRL3 is the Speckle-type POZ protein (SPOP) [139]. 
 
1.2.2 Speckle-type Poxvirus and zinc finger domain (POZ) Protein (SPOP)  
SPOP is a 42kDa protein that was discovered when serum from a scleroderma patient stained 
a novel antigen that was expressed in nuclear speckles in an immunostaining assay. A BLAST 
search revealed that the protein contained a POZ domain thus prompting the scientists to 
name it the Speckle-type Poxvirus and zinc finger domain (POZ) Protein. In addition, the 
protein appeared to be ubiquitously expressed in tissues of different origin [146]. 
Mammalian SPOP substrates include Macro2A-which is involved in the silencing of one of the 
two X chromosomes in a stable manner (X inactivation) through regulating X-chromosome 
deposition; and DAXX- a protein that plays various roles in the life cycle including apoptosis, 
transcriptional regulation and controlling the expression of the vascular endothelial cell 
growth factor receptor 2 (VEGFR2) [147]–[149].  
 
SPOP is a substrate recognition subunit of the Cullin-RING 3 Ubiquitin ligase complex. It has 
an internal bric-a-brac, Tram-track and Broad Complex/Pox virus and Zinc finger (BTB/POZ) 
domain that binds to Cul3, a N-terminal Meprin and TRAF homology (MATH) domain that 
binds to the substrate and a C-terminal domain that contains a nuclear localization signal 
(NLS)- also referred to as the BTB and C-terminal Kelch (BACK) domain (Figure 1.5). These 
domains are flexible, allowing for the formation of multimeric complexes, such that SPOP can 
interact with different motifs on a given substrate [139]. The structure of dimeric SPOP has 
been resolved and Tyr353 was pinpointed as a critical residue in the formation of high-order 
SPOP oligomers [150]. The multimeric complexes are dynamic as dimers readily disassociate 
and re-associate thus giving the speckles a liquid assembly character. These liquid 
(membrane-less) nuclear speckles have been postulated to increase the efficiency of 
ubiquitination through the concentration of functional components. A report by Marzahn and 
colleagues, showed that the BTB and BACK domains in SPOP are crucial for the assembly of 
high order complexes as mutations in either domain impeded multimerization [151]. The 
same group recently demonstrated that SPOP undergoes phase separation when co-
expressed with DAXX in vitro and leaves its nuclear speckles to localize with DAXX in other 
liquid organelles -so called SPOP-DAXX bodies- in cells. Further suggesting that phase 
separation of SPOP -in a substrate-mediated manner- is essential to its function [152]. 
 
The substrates share a SPOP binding consensus sequence (SBC) that is φ-π-S-S/T-S/T (φ-
nonpolar; π-polar). When the crystal structure of the SBCs from different substrates were 
analyzed they displayed similar binding affinities, virtually identical structures and could be 
super-imposed on each other [139]. However, this has been recently challenged, as the 
transcription factor Pdx1 lacks two Ser/Thr residues at position 4 and 5 of the SBC sequence, 
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yet is still able to bind to SPOP. This observation suggests an extended ligand motif for SPOP 
substrates, thus a less stringent- φ-π-S-π-π, (φ: nonpolar; π: polar) SBC was proposed [153]. 
Mutations in key hydrophobic dimerization residues in the BTB domain impaired its ability 
to ubiquitinate target proteins, proving that in its active form SPOP forms homodimers via 
the BTB domains and as a result- two CRL3s [139].  The same phenomenon has been seen 
with TRAF6 and Siah, which are simple RING E3s that contain MATH-domains [154], [155].  
 
Mutations of SPOP have also been proven to play significant roles in several different cancers. 
It exerts tumor-promoting effects by ubiquitinating and degrading several regulators, e.g 
ERK phosphatases, DAXX, tumor suppressor PTEN, and transcription factor Gli2 in renal clear 
cell carcinoma [156]. On the other hand, SPOP plays tumor-suppressing roles by regulating 
Gli2 in gastric and colorectral cancer, progesterone receptors in breast cancer; BET proteins, 
Cyclin-E1, ERG, and EglN2 in prostate cancer and SIRT2 in non-small cell lung cancer [157]–
[164]. These contrasting data have prevented the classification SPOP wholly as a tumor 
suppressor or a tumor promoter. SPOP also interacts with other regulatory pathways such 
as the SUMOylation. For example, it plays a role in the degradation of a Sentrin/SUMO-
specific protease 7 (SENP7) deSUMOylase which results in cellular senescence [165]. 
 
1.2.3 Speckle-type Poxvirus and zinc finger domain (POZ) Protein-Like (SPOPL)  
A paralog of SPOP and the only other human protein to contain a MATH-BTB domain is the 
Speckle-type POZ Protein-Like (SPOPL). It shares 85% sequence identity with SPOP save for 
an extra 18 amino acids, thus increasing its molecular weight to 45kDa (Figure 1.5) [166]. It 
is also widely expressed in different human tissues and is highly conserved within different 
species of vertebrates. But unlike SPOP, SPOPL is localized in endosomes. The endocytic 
adaptor EPS15 has been identified as a substrate of the CRL3 complex with SPOPL, which 
plays a role in the efficient formation of intraluminal vesicles and uncoating of the Influenza 
A virus (IAV) [167].  
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Figure 1.5 Differences between SPOP and SPOPL (Adapted from Errington et al., 2012 
[166])  Protein alignment of the two proteins. SPOP and SPOPL share the same N-terminal 
MATH (orange), and central BTB domains (grey), but SPOPL contains an 18 amino acid insert 
in the BACK domain (blue). Green highlight shows matching amino acids. Alignment was 
done using Clone Manager. MATH- Meprin and TRAF homology, BTB-bric-a-brac, Tram-track 
and Broad domain, BACK- BTB and C-terminal Kelch domain.  
 
SPOPL forms heterodimers with SPOP, however they are less efficient at ubiquitinating target 
proteins. Therefore the SPOP-SPOPL heterodimers are deemed as a ‘molecular rheostat’, 
regulating the way in which SPOP ubiquitinates its targets [166]. When the BACK insert of 
SPOPL (Figure 1.5) was deleted it was able to oligomerize and ubiquitinate target proteins to 
the same level observed with SPOP. Thus, it was ascertained as the sequence that causes less 
efficient heterodimers that disrupt high order oligomers formed by SPOP-SPOP homodimers 
and form less-active CRL3 complexes (Figure 1.6) [166].  
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Figure 1.6 The action of SPOPL on SPOP (Adapted from Errington et al., 2012 [166]). A 
model of how SPOPL modifies the ubiquitination pattern of SPOP.  
 
1.2.4 The ubiquitin-proteasome system and AAV  
Post translational modifications are alterations made to amino acids after translation that 
can result in a change in function or localization. For viruses this could fine tune different 
aspects to do with infectivity or the response in the host cell. Thus allowing for the virus to 
co-evolve/adapt to cellular barriers as seen with vaccinia, polyoma and adenoviruses [168]–
[170]. In a new study looking at PTMs on the AAV capsids from serotypes AAV1-rh10, Mary 
and colleagues identified that out of all the PTMs on the AAV capsids, 17% were modifications 
of a ubiquitin nature, but were serotype-specific [171]. 
 
Ubiquitination of the capsids has been long thought of as detrimental to transduction, given 
that it mostly results in the targeting of capsids to the proteasome for degradation. This was 
confirmed in the initial studies whereby inhibition of the proteasome resulted in increased 
transduction efficacies. Proteasome inhibitor (PI) treatment to the apical surface of polarized 
airway epithelia increased transduction nearly equal level to the level of infection of the 
basolateral surface (>200-fold) and improved the gene transfer to detectable levels in large 
bronchial epithelia in vivo and was 10 fold higher in the liver [172].  
 
Further studies used different PIs to provide insight into how the proteasome restricts AAV 
transduction. A second-generation PI- carfilzomib, claimed to reduce the ‘promiscuity’ seen 
in other PIs by targeting no other proteases and through the specific inhibition of the 
chymotrypsin-like activity of the proteasome. Carfilzomib was able to enhance transduction 
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and gave concrete evidence that proteasome inhibition specifically, with no other off target 
effects, was able to increase AAV transduction. It was proposed to be through the 
accumulation of ubiquitinated capsids that positively affected the late steps in AAV 
transduction [173]. 
 
Newer approaches involve targeting the capsid residues that are presumed to undergo 
ubiquitination. In one study of AAV2 vectors, the modification of 3 out of 7 capsid lysines 
(K532, K544 and double mutant K490+532) resulted in higher transduction efficacies (82–
70%)  compared to AAV2-WT vectors (30%) in vitro and reported up to 4.9-fold increase in 
copy numbers and up 12.7-fold higher transgene expression in vivo [174]. Baozheng and 
colleagues, corroborated these findings as changing 4 out of 10 exposed lysines on the AAV2 
capsid surface (K490, K544, K549, and K556) resulted in up to a 5-fold higher efficiency than 
AAV2-WT vectors in vitro and in vivo. However, when they exchanged these conserved 
lysines on AAV8 (which is better suited to transduce murine hepatocytes) there was no 
change in the transduction efficacy, which pointed to a serotype specific effect [175].  Another 
study exchanged K137 on the AAV8 capsid, resulting in a 40-fold increase in GFP transcripts, 
demonstrated lower capsid ubiquitination; and significantly reduced the activation of the 
innate immune response and the formation of neutralizing antibodies in mice [176].  
 
Phosphorylation has also been proven as a pre-requisite for ubiquitination. In one study, 7 
exposed tyrosine residues on the AAV2 capsid-that were hypothesized to undergo 
phosphorylation via the epidermal growth factor receptor protein tyrosine kinase (EGFR-
PTK)- were modified to phenylalanine and resulted in a 10-fold higher efficiency in vitro and 
nearly 30 fold higher efficiency in vivo with 10-fold lower vector doses. In the same study 
they showed that this was due to better trafficking to the nucleus and escape from 
ubiquitination [177]. Another study showed that changes in 11 serines/threonines on AAV2 
vectors (S/T→A) resulted in higher transduction efficacies (63–97%) compared to AAV2-WT 
vectors (41%) in vitro and reported up to 4.5-fold increase in copy numbers and up 14-fold 
higher transgene expression in vivo [174]. In a study that relied on a systematic 
computational analysis to identify possible serine, threonine and lysine residues of interest 
on the capsid, Sen and colleagues showed that  mutations of two serines on the AAV8 capsids 
resulted in up to 20-fold increase in transcripts in mice [176].  
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1.3 Aim of the Study  
By and large, efforts aimed at modifying specific capsids ubiquitination sites have proven 
successful. Although deeper  insight into  the relations with the E3-ubiquitin ligase complex 
would further enrich our understanding of AAV biology and could additionally provide 
additional targets that could be used to improve AAV vectors. A yeast-2-hybrid screen and a 
tandem-affinity purification (TAP-tag) experiment identified Speckle-type POZ Protein 
(SPOP) as an interaction factor of the AAV capsid protein VP1 [178]. The same study also 
identified the Cullin-RING 3 Ubiquitin ligase (Cul3). This study aims to validate and 
characterize the consequence of this interaction, along with evaluating the contribution of 
other members of the ubiquitin-proteasome pathway- SPOPL and the proteasome. It is 
hypothesized, that SPOP plays a role by possibly regulating the ubiquitination of  AAV capsids 
during entry or of de novo synthesized capsid proteins. Therefore, this study evaluates the 
effect on incoming capsids during AAV entry (Figure 1.7a) and of newly synthesized capsids 
(Figure 1.7b).   
 
 
 
Figure 1.7 Proposed models for the interaction between AAV and SPOP. a. SPOP 
interacts with incoming capsids either leading to proteasomal targeting or culminates in 
successful infection. b. SPOP interacts with newly synthesized capsid proteins before they 
are assembled into capsids (via the interaction with AAP) either for proteasomal targeting or 
for other non-proteolytic functions.  
 
 
The specific aims include- 
 
1. To determine the role of ubiquitination/degradation during AAV infection 
a) Investigate the impact of SPOP, SPOPL, Cul3 and the proteasome on the 
transduction of AAV. 
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b) Study the state of capsid proteins during the infection cycle: 
i. Inspect the degradation state of capsid proteins over time (via dot blot). 
ii. Observe the localization of AAV particles via immunofluorescence. 
iii. Determine the effect of the factors on capsid protein degradation. 
 
2. To determine the role of ubiquitination/degradation on  de novo capsid proteins 
a) Determine the effect of SPOP, Cul3 and the proteasome on newly synthesized 
capsids. 
b) Verify the role of AAP and its interplay with SPOP on the stabilization of capsid 
proteins.   
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2 Materials 
2.1 Biological Materials  
2.1.1 Mammalian Cell Culture 
 
HEK 293TT cells 
HEK 293TT cells are a human embryonic kidney cells containing two copies of the simian 
virus T-antigen. The HEK 293TT cells were cultured in supplemented low glucose Dulbecco’s 
modified Eagle’s Medium (DMEM) with Hygromycin B (62.5 μM) for selection. 
 
HeLa cells 
HeLa cells are human epithelial cervix adenocarcinoma cells containing the HPV 18- genome, 
cultured in supplemented low glucose DMEM. 
 
HEK 293T SPOP K/O and Parental cells 
Wild type Cas9 expressing HEK 293T cells and SPOP Knock out cells (HEK 293T Cas9-Puro 
SPOP-KO) were kindly obtained from Dr. Luca Busino, University of Pennsylvania, 
Philadelphia, USA. The HEK 293T Cas9 cells were transfected with a lentivirus CRISPR 
targeting hSPOP with GFP expression and puromycin resistance. The cells were cultured in 
supplemented high glucose DMEM. 
 
HeLa SPOP K/O and Parental cells 
Wild type HeLa cells and a SPOP Knock out HeLa cell line was obtained from Canopy 
Biosciences Missouri, USA. The cells were cultured in supplemented high glucose DMEM. 
 
HCT 116 cells 
HCT116 are human cells derived from a colon carcinoma with a mutation in codon 13 of Ras. 
The cells were cultured in supplemented low glucose DMEM. 
 
A549 cells 
A549 cells are human epithelial cells derived from a lung carcinoma. The cells were cultured 
in supplemented low glucose DMEM. 
 
Caski cells 
Caski cells are human epithelial cells derived from a metastatic tumor in the small intestine. 
The cells were cultured in supplemented Roswell Park Memorial Institute (RPMI) medium. 
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MCF7 cells 
MCF7 cells are human epithelial cells derived from adenocarcinoma in the mammary glands. 
The cells were cultured in supplemented low glucose DMEM. 
 
2.1.2 Bacterial strains 
 
Strain Genotype 
E. coli MegaX DH10 (Invitrogen) F-mcrA Δ(mrr-hsdRMS-mcrBC) Φ80lacZΔM15 
ΔlacX74 recA1 endA1 araD139Δ(ara,leu)7697 
galU galK λ-rpsL nupG 
E. coli XL-Blue supercompetent 
cells (Agilent Technologies) 
recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 
lac [F´ proAB lacIq Z∆M15 Tn10 (Tetr )] 
E. coli SoloPack (Agilent 
Technologies) 
Tetr Δ (mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 
endA1 supE44 thi-1 recA1 gyrA96 relA1 lac Hte [F′ 
proAB lacIq ZΔM15 Tn10 (Tetr ) Amy Camr ] 
 
2.1.2.1 Bacterial culture 
 
LB agar plates 
98.5% LB medium  
1.5% bacto-agar  
Autoclaved, supplemented with appropriate antibiotics  
 
LB medium 
10 g Tryptone 
5 g yeast extract 
5 g NaCl 
Adjust final volume to 1 l with Millipore H2O, pH 7.5, autoclaved 
 
SOC Media (Invitrogen, California, USA) 
 
Antibiotics 
Ampicillin final concentration: 100 μg/mL 
Kanamycin final concentration: 25 μg/mL 
Spectinomycin final concentration: 100 µg/ml 
Chloramphenicol final concentration: 20 µg/ml 
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2.1.3 Viruses  
 
Viruses were produced by transfection of HEK293T(T) cells with the respective plasmids 
 
 Virus Plasmids 
AAV2-firefly luciferase #2772 + #1814 + #1995 
AAV2 Wildtype #3668 + #1814 + #3541 
AAV2 Wildtype  
(stop in AAP) 
#3622 + #1814 + #2958 
AAV2 Wildtype  
(stop in AAP + AAP in trans) 
#3622 + #1814 + #3651 
AAV2 Wildtype  
(no AAP ORF) 
#3623 + #1814 + #2958 
AAV2 Wildtype 
(no AAP ORF + AAP in trans) 
#3623 + #1814 + #3651 
2.2 Molecular Biology Materials  
2.2.1 Plasmids  
 
Plasmid 
Number 
Plasmid  
description 
 
Reference 
1814 pDGΔVP, AAV2/Ad-helper plasmid without cap-gene A. Sacher   
1995 Firefly luciferase reporter construct M. Müller 
2772 pDP2-> AAV2 wt cap without ITRs, with helper functions  M. Müller 
2951 SPOP cDNA (closed) in pENTR221 (Gateway compatible) GPCF, DKFZ 
2958 N-Myc, Gateway compatible vector (DEST) GPCF, DKFZ 
2976 N-Myc-SPOP (#2951 in MycDEST #2958/Gateway) F. Burkart 
3104 pKEX-VP1 J. 
Kleinschmidt 
3172 pKEX VP1 N-terminus (until start of VP3); CMV Promotor F. Burkart 
3263 pKEX VP3; CMV Promotor J. 
Kleinschmidt 
3440 pKEX VP1 N-terminus (until start of VP2); CMV Promotor This thesis 
3441 pKEX VP2 and VP3; CMV Promotor This thesis 
3510 AAP from AAV2 WT   J. 
Kleinschmidt 
3520 Dominant negative SPOP mutant: Amino acid mutation on position 
133 from F->V) on (#2976 N-Myc-SPOP) 
This Thesis 
3521 AAV2 (#2772) with mutation on AAP start codon This Thesis 
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3522 pKEX-VP1 (#3104) with mutation on AAP start codon This Thesis 
3531 AAP in pENTR221 (Gateway compatible) GPCF, DKFZ 
3532 VP2 in pENTR221 (Gateway compatible) GPCF, DKFZ 
3541 VP2 in N-eGFP Destination Vector (3512+3532, Gateway) Q. Chen 
3542 VP2 in N-HA Destination Vector (3513+3532, Gateway) Q. Chen 
3543 VP2 in N-RFP Destination Vector (3514+3532, Gateway) Q. Chen 
3623 pTAVORF1cm- AAV2 WT w/o 2nd ORF J. 
Kleinschmidt 
3622 pTAVORF2stopB- AAV2 w/ STOP in AAP J. 
Kleinschmidt 
3668 pTAV 2.0- AAV-2 genome WT J. 
Kleinschmidt 
3669 pDEST24 C-GST GPCF, DKFZ 
3670 SPOP-L (open construct) GPCF, DKFZ 
3708 His-Padre-Trx-SPOPL This thesis 
3716 psPAX2 (2nd generation lentivirus packaging plasmid) C. Odenwald 
3717 pMD2.G (2nd generation lentivirus packaging plasmid) C. Odenwald 
3731 SPOPL-GST I This thesis 
3651 AAP entry clone in pDEST N-Myc vector This thesis 
3854 SPOPL in C-Myc construct This thesis 
3855 SPOPL in pDEST without a tag This thesis 
3888 eGFP-VP2 only (Stop codon added to 3542 to silence VP3) Q. Chen 
3889 eGFP-VP2 only (Stop codon added to 3542 to silence VP3) Q. Chen 
3891 VP2 until VP3 (Gateway clone of #3887+#2960) Q. Chen 
4013 SPOP-pWpI- Lentiviral construct with Blasticidin resistance This Thesis 
 
2.2.2 Oligonucleotides 
 
2.2.2.1 Site-Directed Mutagenesis (QuikChange) 
 
Primer to stop generate VP-1 unique N-terminus 
Fwd.: 5’ – TTGAGGAACCTGTTAAGTAGGCTCCG– 3’ 
Rev.: 5’ – TTCCCGGAGCCTACTTAACAGGTTCC– 3’ 
 
Primer to silence the VP1 start codon 
Fwd.: 5’ – GATCCCAAATCAGGTGCGGCTGC– 3’ 
Rev.: 5’ – AACCATCGGCAGCCGCACCTGATTTG– 3’ 
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Primer to introduce a Stop codon to AAP 
Fwd.: 5’ – TACAGGCAGTGGCGCACTAATGGCAGAC– 3’ 
Rev.: 5’ – GTCTGCCATTAGTGCGCCACTGCCTGTA– 3’ 
 
2.2.2.2 qPCR primers 
 
SPOP:   
Fwd.: 5’ – GAGAATTCCCGGTTCACAGA– 3’ 
Rev.: 5’ – GCACTAAAAACCGGAGAACG– 3’ 
 
SPOPL:  
Fwd.: 5’ – ATTAATAGGTGCAGTGTACTTCG– 3’ 
Rev.: 5’ – TGCTTGGTTGCTGTTCCAGTT– 3’ 
 
Sae2 primers: 
Fwd.: 5’ –  AAAAAGGGTGTGACCGAGTG– 3’ 
Rev.: 5’ – GCATCTTCTTCCCCAAACAA– 3’ 
 
Cul3 primers: 
Fwd.: 5’ –   TCCAGGGCTTATTGGATCTG– 3’ 
Rev.: 5’ –  CAGGAGACCTGGAGTTGAGG– 3’ 
 
2.2.2.3 siRNA sequences (Eurofins, Ebersberg, Germany) 
 
siSPOP1  
TCAGTTTATCATTTGCTCC 
 
siSPOP2  
GGCTCACAAGGCTATCTTATT 
 
siSPOP3  
GGAGGAAAUGGGUGAAGUCAU 
 
siCUL3  
AACAACTTTCTTCAAACGCTA 
 
siSPOPL 
CAGTTTGGCATTCCACGCAAA 
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2.2.2.4 CRISPR crRNAs 
 
SPOP crRNA1  
ATTGCTTCAGGCGTTTGCGT 
 
SPOP crRNA2  
AGAGTCAACGGGCATAT 
 
SPOP crRNA5  
GTTACTGGTCAGCTGTCCAA 
2.3 Media and Supplements 
2.3.1 General mammalian cell culture  
 
Media 
Dulbecco’s modified Eagle’s Medium-low and high glucose (Sigma Aldrich, Deisenhofen, 
Germany)  
RPMI medium- growth medium developed at Roswell Park Memorial Institute (Sigma 
Aldrich, Deisenhofen, Germany)  
 
supplemented with 10% fetal calf serum, 1% penicillin/streptomycin, 1% L-Glutamine  
 
Cell culture antibiotics 
Hygromycin B- final concentration of 62.5 μM 
Blasticidin-final concentration of 5µg/mL in HeLa and 20µg/mL in HEK 293T cells 
 
Cryomedium 
60% DMEM, non-supplemented 
30% FCS 
10% DMSO 
 
Supplements 
FCS (PAN Biotech, Aidenbach and Gibco, Pawasleyy, UK) 
penicillin/streptomycin (GIBCO, Eggenstein, Germany) 
L-glutamine (Sigma-Aldrich, Deisenhofen, Germany) 
 
Disassociation media 
0.05% and 0.25% Trypsin-EDTA (Gibco, Eggenstein, Germany) 
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Transfection reagent 
HiPerFect® transfection reagent (Qiagen, Hilden, Germany) 
 
2.3.2 Fusion – Hybridoma Generation  
 
HAT-Media  
45ml inactivated FCS 
3ml pen/strep 
1ml 1M Hepes pH 7.2 + 0,2% β-mercaptoethanol  
0.5ml 50x HFCS (Roche, Mannheim, Germany) 
9ml HAT media supplement (50x) HybriMaxTM (Sigma, St. Louis, USA) 
Adjust to final volume of 300ml with non-supplemented RPMI 
 
Feeder-Medium 
45 ml inactivated FCS 
3ml pen/strep 
1ml of HFCS 
splenocytes of entire spleen of a mouse 
Adjust to final volume of 300 ml with non-supplemented RPMI 
 
PEG 
Poly (ethylene glycol) solution 50%(w/v) (Sigma, Taufkirchen, Germany) 
 
2.3.3 Molecular Biology reagents 
 
2.3.3.1 Quantitative PCR 
 
SsoAdvanced© Universal SYBR® Green Supermix (Bio-Rad Laboratories, California, USA) 
 
2.3.3.2 Agarose gel-Electrophoresis 
 
1% Agarose gel 
1g agarose dissolved in 100 mL TAE running buffer by heating and 7µL ethidium bromide 
(Roth, Karlsruhe, Germany) was added. 
 
1x TAE running buffer 
40 mM Tris 
5.71% acetic acid  
10% 0.5 M EDTA, pH 8  
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In Millipore H2O 
 
Loading buffers and markers 
6x loading buffer (ThermoFisher Scientific, Waltham, USA) 
1kb DNA ladder plus (NEB, Schwalbach, Germany) 
100 bp DNA ladder plus (NEB, Schwalbach, Germany) 
Lambd/HindIII DNA ladder (NEB Biolabs, Schwalbach, Germany) 
 
2.3.3.3 Enyzmes 
 
Topoisomerase I (NEB Biolabs, Schwalbach, Germany) 
Q5® High-Fidelity DNA Polymerase (NEB Biolabs, Schwalbach, Germany) 
T4 Ligase (NEB Biolabs, Schwalbach, Germany) 
Clonase™ II enzyme mix (ThermoFisher Scientific, Waltham, USA)  
Multiscribe™ Reverse Transcriptase (ThermoFisher Scientific, Waltham, USA) 
PfuUltra HF DNA Polymerase (Agilent Technologies, La Jolla, USA) 
all restriction enzymes (NEB Biolabs, Schwalbach, Germany) 
 
2.3.4 Materials for virological methods 
 
2.3.4.1 Solutions for vector production 
 
AAV Lysis Buffer 
50 mM Tris, pH 8.5 
150 mM NaCl 
In Millipore H2O, pH 8.5, autoclave 
 
PBS-MK/NaCl 
1 M NaCl in PBS-MK, filter-sterilized 
 
PBS-MK 
1 mM MgCl2 
2.5 mM KCl 
In PBS, filter-sterilized 
 
Iodixanol 
60% iodixanol (Sigma-Aldrich, Taufkirchen, Germany) 
 
Opti-MEM (ThermoFisher Scientific, Waltham, USA) 
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2.3.4.2 Proteasome and Cul3 inhibitors 
 
Pevonedistat (MLN4924)- (Biozol, Eching, Germany) 
(S)-MG-132 (Cayman chemicals, Ann Arbor, Michigan, USA) 
Bortezomib (Focus Biomolecules, Plymouth, Pennsylvania, USA) 
 
2.3.5 Protein analysis materials 
 
2.3.5.1 Determination of protein concentration 
 
Bradford reagent (BioRad, Munich, Germany) 
BSA standard (2 μg/μl) (ThermoFisher Scientific, Waltham, USA) 
 
2.3.5.2 SDS-polyacrylamide gel Electrophoresis 
 
Preparation of SDS-polyacrylamide gels 
 
Tris buffer, pH 8.8 
1M Tris 
In H2O, pH 6.8 
 
Tris buffer, pH 6.8 
1 M Tris 
0.03% bromophenol blue 
In H2O, pH 6.8 
 
acrylamide solution (Roth, Karlsruhe, Germany) 
ammonium persulfate (Serva Electrophoresis GmbH, Heidelberg)  
TEMED (Sigma-Aldrich, Deisenhofen Germany) 
 
Recipe for five mini SDS-gels 
Component 3% Stacking gel 12.5% Running gel 
30% acrylamide  1 mL  18.75 mL  
1 M Tris buffer  1.3 mL (pH 6.8) 16.88 mL (pH 8.8)  
H2O  7.5 mL  8.48 mL  
10% SDS  100 μL 450 μL 
10% APS  100 μL 450 μL 
TEMED 15µL 22.5µL 
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Sample preparation 
 
3x protein loading buffer 
30% glycerol 
6% SDS 
15% β-mercaptoethanol 
0.03% bromophenol blue 
187.5 mM Tris 
In H2O, pH 6.8 
 
Electrophoresis 
 
1x TGS buffer (running buffer) 
2.5 mM Tris 
1.45% glycine 
0.1% SDS 
In H2O, pH 8.3 
 
Prestained protein ladder color plus (NEB Biolabs, Schwalbach, Germany) 
 
2.3.5.3 Dot Blot analysis 
 
Stratagene’s dot blot chamber (Stratagene, California, USA) 
Laboratory pumps (BioRad, Munich, Germany)  
Silicone vacuum grease (Beckman Coulter GmbH, Krefeld, Germany) 
 
2.3.5.4 Western Blot analysis 
 
1x NuPAGE® Wet blot transfer (Invitrogen, California, USA) 
10mL NuPAGE® wet blot transfer 
0.1mL NuPAGE® antioxidant 
10mL Methanol 
79.9mL Millipore H2O 
 
1xPBS-T (wash buffer) 
0.03% Tween 20  
In 1xPBS 
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Blocking solution 
5% milk in PBS-T 
2.4 Immunological materials 
2.4.1 Antibodies  
Type Description  Reference 
A20 Mouse monoclonal antibody raised against VP1 
capsid of various AAV serotypes 
J. Kleinschmidt 
A69 Mouse monoclonal antibody raised against VP1 and 
VP2 capsid proteins of various AAV serotypes 
J. Kleinschmidt 
B1 Mouse monoclonal antibody raised against VP1, VP2 
and VP3 capsid proteins of various AAV serotypes 
J. Kleinschmidt 
LN6 Mouse monoclonal antibody raised against GST-
SPOP 
G. Jaschkowitz 
Anti-SPOP 
polyclonal sera 
Guinea pig sera raised against the SPOP protein This thesis 
Anti-SPOPL 
polyclonal sera 
Guinea pig sera raised against the 18aa insert of 
SPOPL  
This thesis 
SPOP  Rabbit polyclonal, binds to a synthetic peptide 
corresponding a region of human SPOP 
ProSci 
Cul 3  Rabbit polyclonal antibodies produced against a 
synthetic peptide corresponding to residues 
surrounding Leu750 of human Cullin-3 
Cell Signaling 
Technologies 
Anti-PML The epitope recognized by PLA0172 maps to a 
region between residue 375 and 425 of 
promyelocytic leukaemia using the numbering given 
in entry NP_150241.2 (GeneID 5371). 
Sigma Aldrich 
Anti-actin  
(clone C4) 
Mouse monoclonal antibody against residue 18-40 
of chicken gizzard skeletal muscle actin 
MP Biomedicals  
Anti-Histone H3 
(di methyl k4) 
[EPR17707] 
Rabbit monoclonal antibody against Human Histone 
H3 (di methyl K4) 
Abcam 
GAMPO HRP-coupled Goat-anti-mouse antibody Dianova 
GARPO HRP-coupled Goat-anti-Rabbit antibody Dianova 
DAGPO HRP-coupled Donkey-anti-goat antibody Santa Cruz 
Alexa Flour 488 Alexa Flour 488-coupled Goat-anti-mouse antibody Life 
Technologies 
Alexa Flour 488 Alexa Flour 488-coupled Goat-anti-rabbit antibody Life 
Technologies 
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Alexa Flour 594 Alexa Flour 594-coupled Goat-anti-mouse antibody Life 
Technologies 
Alexa Flour 594 Alexa Flour 549-coupled Goat-anti-rabbit antibody Life 
Technologies 
 
2.4.2 Immunofluorescence 
 
Fixation 
4% PFA in 200 mM HEPES, pH 7.4 
 
Quenching 
50 mM ammonium chloride 
 
Permeabilization 
0.2% triton-X 100 in PBS 
 
Blocking solution 
1% BSA in PBS 
 
DAPI 
100 mg/ml in PBS 
 
Mounting medium (Dianova, Hamburg, Germany) 
 
1xPBS 
140 mM NaCl 
2.7 mM KCl 
8.1 mM Na2HPO4 
1.5 mM KH2PO4 
In Millipore H2O, pH 7.4, autoclave 
 
Methanol (Sigma-Aldrich, Deisenhofen, Germany) 
Ethanol (VWR, Darmstadt, Germany) 
Butanol (Applichem, Darmstadt, Germany) 
Isopropanol (VWR, Darmstadt, Germany) 
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2.5 Chemicals 
All chemicals were purchased from Sigma-Aldrich (Taufkirchen), AppliChem (Darmstadt), 
Merck (Darmstadt), Roth (Karlsruhe), Serva (Heidelberg), Fluka (Neu Ulm), Gerbu (Gaiberg), 
VWR (Darmstadt) and Life Technologies (Karlsruhe). 
 
Kits 
Item Company 
Gateway® LR Clonase™ II Enzyme mix  Life Technologies, Karlsruhe, Germany 
Beetle-Juice  PJK, Kleinbittersdorf, Germany 
Chemiluminescence kit  AppliChem, Darmstadt, Germany 
Qiagen Maxi Kit  Qiagen, Hilden, Germany 
QIAprep Spin Miniprep kit  Qiagen, Hilden, Germany 
QIAquick Gel extraction kit  Qiagen, Hilden, Germany 
QIAquick PCR Purification Kit  Qiagen, Hilden, Germany 
QuikChange® II Site-directed mutagenesis 
Kit  
Agilent Technologies, La Jolla, USA 
High capacity cDNA Reverse Transcription 
kits  
ThermoFisher Scientific, Waltham, USA 
Rneasy© Mini Kit  Qiagen, Hilden, Germany. 
Gateway® LR Clonase™ II Enzyme mix  Life Technologies, Karlsruhe, Germany 
 
2.6 Electrical equipment 
Cell culture hoods 
Item Company 
Bio GARD cell culture hood  The Baker Company, Sanford, USA   
Steril GARD III Advance cell culture hood  The Baker Company, Sanford, USA 
 
Centrifuges 
Item Company 
Refrigerated Sorvall RC6+ centrifuge  ThermoFisher Scientific, Waltham, USA   
Refrigerated table-top centrifuge 5417R  Eppendorf, Hamburg, Germany   
Table top centrifuge 5415C  Eppendorf, Hamburg, Germany   
Ultracentrifuge Sorvall Discovery 90 SE  ThermoFisher Scientific, Waltham, USA   
Megafuge 1.0 Heraeus, Hanau, Germany   
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Centrifuge rotors 
Item Company 
Fiberlite™ F12-6 x 500 LEX Fixed Angle 
Rotor  
ThermoFisher Scientific, Waltham, USA   
Fiberlite™ F13-14 x 50cy Fixed Angle Rotor  ThermoFisher Scientific, Waltham, USA   
TFT65 Fixed Angle Rotor  ThermoFisher Scientific, Waltham, USA   
 
Freezer and fridges 
Item Company 
Liebherr Comfort  Liebherr, Biberach, Germany   
Liebherr MedLine  Liebherr, Biberach, Germany   
Liebherr Premium  Liebherr, Biberach, Germany   
Liebherr ProfiLine  Liebherr, Biberach, Germany   
Ultra-low freezer  Heraeus, Hanau, Germany   
 
Incubators 
Item Company 
Function Line incubator  Heraeus, Hanau, Germany   
Sanyo CO2 incubator  Sanyo/Panasonic Healthcare Company, 
Wood Dale, USA   
 
Microscopes 
Item Company 
Leitz Diavert  Diavert Leitz, Wetzlar, Germany   
Will Wilovert  Wilovert Hund, Wetzlar, Germany   
Zeiss Cell Observer  Zeiss, Jena, Germany   
FV3000, Confocal Laser Scanning 
Microscope 
Olympus, Hamburg, Germany 
 
Electrophoresis 
Item Company 
Polyacrylamide Gel Electrophoresis 
Chamber  
Hoefer, San Francisco, USA   
Xcell SureLock™ MiniCell Electrophoresis 
System  
ThermoFisher Scientific, Waltham, USA   
Transblot SD chamber  BioRad, Munich, Germany   
Agarose Electrophoresis chamber BioRad, Munich, Germany   
Electrophoresis power supply ST PS 305  Gibco BRL, Eggenstein, Germany   
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Plate reading equipment 
Item Company 
1420 Multilabel Counter Viktor3  Perkin Elmer, Norwalk, USA   
Multiskan Go microplate 
spectrophotometer  
ThermoFisher Scientific, Waltham, USA   
PreCision 50-1200 μL-multichannel  Biozym, Hesswasch-Oldendorf, Germany   
 
Shakers, Mixers and water baths 
Item Company 
Bacterial culture shaker  Informs AG, Bottmingen, Switzerland   
Combimage Red/RET magnetic stirrer  IKA, Staufen, Germany   
Test-tube-rotator  Snijders Scientific, Tilburg, Netherlands   
Thermomixer 5436  Eppendorf, Hamburg, Germany   
Thermomixer comfort  Eppendorf, Hamburg, Germany   
Duomax 1030 shaker  Heidolph, Schwabach, Germany   
Table-top Shaker  GFL, Burgwedel, Germany   
Vibramax-VXR  IKA, Staufen, Germany   
Vortex Genie 2TM  Bender and Hobein, Wasmaning, Germany   
GFC Waterbaths  Grant Instruments, Cambridge, UK   
UC water bath  Julabo, Seelbach, Germany   
 
Others 
Item Company 
Integra pipetboy  Integra Biosciences GmbH, Fernwald, 
Germany   
800 W microwave  Bosch, Gerlingen-Schillerhöhe, Germany   
C1000 Touch Thermal Cycler  BioRad, Munich, Germany   
CFX96 Touch™ thermocycler  BioRad, Munich, Germany   
Electrophoresis power supply ST PS 305  Gibco BRL, Eggenstein, Germany   
Gel Doc EZ Imager  BioRad, Munich, Germany   
Ice maker  Hoshizaki, Willich-Munchheide, Germany   
Impulse Sealer  RNS Corp., Taipei, Taiwan   
MicroPulser™ Electroporator  BioRad, Munich, Germany   
MilliQ ultra-pure water unit Millipore  Merck, Darmstadt, Germany   
Nanodrop spectrophotometer  PegLab, Erlangen, Germany   
Nitrogen tank  Chrono Messer, Krefeld, Germany   
pH meter  Sartorius, Göttingen, Germany   
Sartorius scale  Sartorius AG, Göttingen, Germany   
Transblot SD chamber  BioRad, Munich, Germany   
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Western Blot developing machine Agfa, Mortsel, Belgium   
X-Ray cassette  Kodak, Stuttgart, Germany   
 
Common use utensils 
Item Company 
1.5 mL and 2.0 mL microcentrifuge tubes Eppendorf, Hamburg, Germany 
10 mm cover slips ThermoFisher Scientific, Waltham, USA  
10 cm culture plates Greiner, Frickenhausen, Germany  
15 mL reaction tubes TPP, Klettgau, Switzerland  
14mL BD falcon round-bottom tube BD biosciences, 2 Oak Park, Bedford, USA  
25, 75 and 150 cm2 Tissue culture flasks TPP, Klettgau, Switzerland  
50 mL reaction tubes Greiner, Frickenhausen, Germany  
6, 10 and 15 cm cell culture dishes Sarstedt Inc., Newton, USA  
6-, 12-, and 24-well test plates TPP, Klettgau, Switzerland  
96-well LIA plate Greiner, Frickenhausen, Germany  
96-well plate Costar Corning, USA  
Ultracentrifuge tubes Beckman Coulter GmbH, Krefeld, Germany  
Cell lifter Costar Corning  
Chemiluminescence films GE Healthcare Limited, Buckinghamshire, 
UK  
Cryo tubes, 2 ml Roth, Karlsruhe, Germany  
Electroporation cuvettes  25 x 2 mm Peqlab, Erlangen, Germany  
Glass slides   ThermoFisher Scientific, Waltham, USA 
Inoculating loop   Greiner, Frickenhausen, Germany 
Nitrocellulose membrane   Schleicher & Schuell, Dassel, Germany 
One-time use filter, 0.2/0.4 μm   Renner, Darmstadt, Germany 
Parafilm “M”   American National Can, Chicago, USA 
Pipette tips   Nerbe plus GmbH, Winsen/Luhe, Germany 
Pipettes  1000, 200, 100, 20, 10 and 2 μL    Gilson, Middleton, USA 
Syringes and needles   BD Franklin Lakes, USA 
Whatman filter paper 3MM paper   
 
Schleicher & Schuell, Dassel, Germany 
 
Software 
Software Company 
Adobe CS4/CS6 Adobe, San Jose, USA 
Clone Manager 9.0 for Windows Scientific & Educational Software, Cary, 
USA 
Mendeley Elsevier, Amsterdam, Netherlands 
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GraphPad Prism 5.0 GraphPad Software, La Jolla, USA 
ImageJ 1.40 NIH, Bethesda, USA 
Microsoft Office 2003, 2010 Microsoft, Redmont, USA 
Microsoft Windows XP, 8.1 Microsoft, Redmont, USA 
Wallac 1420 Workstation Perkin Elmer, Norwalk, USA 
ZEN Black Zeiss, Jena, Germany 
Multiskan Go 3.2 ThermoFisher Scientific, Waltham, USA 
CFX Manager™ Software Bio-Rad Laboratories, California, USA 
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3 Methods 
3.1 Cell culture methods 
3.1.1 Cell culture maintenance 
Cells were grown in 175cm2 flasks and split when they reached 75-90% confluency. To do so, 
the media was aspirated off the cells and they were washed with 1xPBS and then treated with 
0.05-0.25% trypsin-EDTA for 5 minutes at 37°C to detach the cells. The trypsin was 
neutralized with supplemented media and the cells were split according to the needs of 
future experiments. The appropriate amount of media was then added to the flask and the 
cells were grown at 37℃, 5% CO2 and 90% humidity. For the experiments, the cells were 
harvested and counted using a Neubauer chamber and diluted according to the appropriate 
need. 
3.1.2 Cryopreservation 
Cells from a confluent 175cm2 flask were frozen as follows. The media was aspirated off the 
cells and they were washed with 1xPBS and then treated with 3mL trypsin for 5 minutes at 
37°C. 7mL of supplemented media was added to the cells and they were collected in a 15mL 
tube. The cells were pelleted at 1500rpm for 10minutes, supernatant was aspirated, and the 
cells were re-suspended in 1mL cryomedium and transferred to a labeled cryovial. The vial 
was placed in an isopropanol tank overnight at -80°C and the cells were thereafter 
transferred to liquid nitrogen for long term storage. 
3.1.3 siRNA transfections 
8x104 cells were seeded on 24-well plates a day prior to the experiment to allow for stable 
growth. The next day the cells were treated with a transfection mix made of 40nM siRNA, 3µL 
Hiperfect and 100µL un-supplemented DMEM per well that was incubated for 7 minutes then 
added to the cells in a drop-wise fashion before incubation for 48 hours at 37°C 5% CO2 and 
90% humidity. After the knockdown the cells were either harvested for western blot, qPCR 
or were transduced with virus. 
3.1.4 Transfection with PEI 
The appropriate number of cells was seeded on a plate/dish and transfected as follows: 
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Table 3.1- Overview of cells amounts and transfection mixes for different plate formats 
Tissue 
culture 
plate  
Number 
of cells  
Volume 
of H2O 
(µL)  
Amount 
of DNA 
(μg)  
Volume of un-
supplemented 
DMEM (mL) 
Volume 
of PEI   
(μL)  
Volume of 
supplemented 
DMEM (mL) 
24-well 
plate  
7 x 104  2.5  0.375  0.07 1.25  0.2 
12-well 
plate  
1 x 105  5  0.75  0.13 2.5  0.4 
6-well 
plate  
2.5 x 105  10  1.5  0.25 5  0.75 
10 cm 
dish  
3.5 x 106  61.5  10  1.6 31  4.6 
15 cm 
dish  
7 x 106  185  27  4.6 92.5  13.8 
 
According to the plate format chosen for the experiment the appropriate volumes of water, 
DNA, un-supplemented DMEM and PEI were mixed thoroughly and incubated for 10 minutes 
before adding the supplemented DMEM. Media was aspirated from the cells and the 
transfection mix was added to the cells for 4 hours before it was replaced by 5% 
supplemented DMEM and incubated at 37°C 5% CO2 and 90% humidity for 6-72 hours. 
3.1.5 CRISPR-Cas9 transfection 
All materials were obtained, and procedures followed according to manufacturer’s protocols 
(GE Healthcare). Briefly, 1x105 HEK 293TT cells that were stably transduced with a Cas9 
lentivirus (by Dr. Caroline Odenwald) were seeded on a 24-well plate a day prior to allow for 
stable growth overnight. The next day a transfection mixture made of 1.25µL 10µM tracrRNA 
and 1.25µL 10µM crRNA (designed to target the gene of interest) in 47.5µL un-supplemented 
media; and 1µL of dharmaFECT 1 reagent in 49µL un-supplemented media, were incubated 
separately for 5 minutes before being mixed together by gently pipetting up and down; and 
incubated for 20 minutes at room temperature. The transfection mix was then diluted in 
400µL antibiotic-free supplemented media, added to the cells and then incubated for 48-72 
hours at 37°C 5% CO2 and 90% humidity. All wells (except A1) of a 96-well plate were filled 
with 100µL of supplemented media.  After the transfection, the cells were counted, with the 
help of a 37Neubauer chamber, 200µL 2x104 cells were placed in the well A1 and 100µL was 
transferred down the wells of the first column from A-H with gentle pipetting up and down. 
The same procedure was repeated from column 1-12 with a multichannel pipette ensuring a 
1:2 dilution across the plate. 100µL of supplemented media was then added to all wells and 
they are incubated at 37°C 5% CO2 for 7-10 days. Single colonies were isolated, grown out 
and tested for a successful knock out using western blot methods. 
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3.1.6 Hybridoma production 
HAT Media and 1.5mL PEG were pre-heated in a water bath. SP2/0 cells were harvested and 
centrifuged at 2000rpm for 5 minutes then washed twice in un-supplemented RPMI. The cells 
were counted with the help of a 38Neubauer chamber and 3x108 cells were resuspended in 
30mL RPMI. The spleens of immunized and naïve mice were removed and added to a 10mL 
tube on ice. It was thereafter homogenized on a sterile net using the stump of a 5mL syringe, 
the spleenocytes were transferred back to the tube, centrifuged at 2000rpm for 5 minutes 
and washed two times with un-supplemented RPMI. This resulted in the fusion and feeder 
cells respectively. The fusion cells were mixed with the SP2/0 cells and centrifuged once 
more at 2000rpm for 5 minutes and the feeder cells were added to the pre-warmed HAT-
media. The Fusion cell-SP2/0 cell mix was submerged a beaker was filled with warm water 
and the pellet was gently stirred with a sealed glass pipette. 1.5mL of PEG was added under 
continuous stirring for 90 seconds then 1mL of un-supplemented RPMI in 1 minute, 3mL in 
1 minute and 16mL in 2 minutes. The cell mixture was centrifuged at 2500rpm for 10 minutes 
and then incubated at room temperature for 5 minutes. The supernatant was carefully 
removed, and the pellet was mixed with HAT-medium before 150µL was spread onto 96-well 
plates using a multichannel pipette, then the plates were incubated for 7-10 days at 37°C 5% 
CO2 and 90% humidity. Single colonies were isolated, grown out and tested for a successful 
monoclonal antibody against the protein of interest. 
3.2 Virological methods 
3.2.1 AAV2 Virus production 
AAV2-reporter vectors were produced from a set of five 15cm dishes seeded with cells. The 
cells were transfected as described above (PEI transfection) with: 3.22µg pDGΔVP (#1814), 
27.74µg Cap construct and 24µg Reporter construct (often firefly luciferase) for 48-72 hours. 
The cells were dislodged using a cell scraper and transferred to two 50mL tubes and spun 
down at 1500rpm for 10-15 minutes. The suspensions were discarded, and the pellets 
washed once with 1xPBS and transferred into a single tube. After a second centrifugation 
round, the pellet was resuspended in AAV lysis buffer and cells were subjected to 5 freeze-
thaw cycles before Benzonase was added at 50U/mL lysate and incubated at 37°C for 30 
minutes. The lysate was thereafter centrifuged at 5000rpm for 10 minutes then added to base 
of the Iodixanol gradient, followed by 1.5mL of 15% Iodixanol in PBS-MK+1M NaCl, then 
1.5mL 25% Iodixanol in PBS-MK+3µL Phenol red, then 1.5mL 40% Iodixanol in PBS-MK and 
finally 3.8mL of 60% Iodixanol + 5µL phenol red. The gradients are carefully balanced to 
0.00g, sealed then placed in an ultracentrifuge at 50,000rpm at 10°C for two hours. After the 
run, the virus was harvested in the 40% Iodixanol phase, aliquoted and stored at -20°C. An 
aliquot was also sent for qPCR for the titer determination.  
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3.2.2 AAV2 quantification 
The AAV genome titer was quantified using quantitative real time PCR. The procedure was 
conducted by the group of Barbara Leuchs (DKFZ, Heidelberg).  
3.2.3 AAV2 transduction assays 
The appropriate number of cells were seeded on a plate/dish and were infected with 
MOI=103 for transduction experiments, MOI= 104 for characterization by western blot and 
MOI= 105 for immunofluorescence experiments. The AAV2-firefly luciferase vectors were 
transduced either alone or in the concert with proteasome inhibitors for 4 hours then 
substituted with supplemented media and incubated at 37°C, 5% CO2 and 90% humidity for 
6-72 hours. Thereafter the cells were either harvested for immunofluorescence, western blot 
or luciferase assays. For the detection of the transduction of luciferase the media was 
aspirated from the cells and incubated with 100µL 1x lysis buffer (PJK) for 15 minutes. 
Thereafter the lysate was transferred to white bottom 96-well plates in triplicate and 
incubated with beetle juice for 1 minute before readout. 
3.2.4 Lentivirus production 
Low passage HEK 293TT cells were cultures in a 75cm flask until fully confluent then 
trypsinized and a third of the cells were seeded onto three 10cm dishes and allowed to grow 
for 48 hours. On the day of transfection, in the first tube- 4ug pMD2.G (#3716), 4ug pSPAX 
(#3717) and 8ug SPOP-pWpI- Lentiviral construct (#4013) were diluted in Opti-MEM, up to 
a total volume of 250µL. In a second tube- 48µL PEI was diluted in 202µL of Opti-MEM and 
both tubes were combined and incubated for 20 minutes at room temperature. The media on 
the cells was replaced with DMEM 10%FCS w/o antibiotics and the transfection mix was 
added dropwise to the dish, while shaking and the dishes were incubated at 37°C, 5% CO2 
and 90% humidity. The following day, the media was changed and on the second and third 
day after transfection the media on the cells (containing released lentivirus) was collected 
and pulled. The media was filtered and centrifuged at 19,400rpm for 2 hours at 20°C. The 
supernatant was thereafter discarded and 150µL Opti-MEM was added to the tube, sealed 
with parafilm and incubated overnight at 4°C. The next day 20µL aliquots were prepared and 
stored at -80°C for long term storage.  
3.2.5 Lentivirus infection 
In order to infect cells with the SPOP lentivirus, 3x106 SPOP Knock out cells were plated on a 
10cm dish a day prior to allow for stable growth. The next day, the cell medium was replaced 
with fresh supplemented DMEM containing 4μg/ml of Polybrene. The plate was swirled 
gently and 20µL lentivirus was added in a dropwise fashion. The cells were incubated at 37°C, 
5% CO2 and 90% humidity overnight. The following day the media was changed, the cells 
were observed for the next two days and underwent blasticidin selection on the third day 
after infection (at a final concentration of 5µg/mL in HeLa and 20µg/mL in HEK 293T cells). 
The cells were further observed for cell death and the media containing the antibiotic was 
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changed two days later. The cells surviving thereafter were considered stably- lentivirus 
infected and tested for the recovery of SPOP, via western blot. After this was confirmed the 
cells were expanded further and cryopreserved for future use. 
3.3 Molecular Biology methods 
3.3.1 DNA purification 
All DNA was obtained from 250mL or 2mL of bacterial cultures harboring the plasmid of 
interest that were purified using the Qiagen Maxiprep and miniprep kits respectively 
according to manufacturing instructions. 
3.3.2 Determination of the DNA concentration 
The concentration of purified DNA was determined using a Nanodrop against a blank of the 
buffer that the DNA was dissolved in. This was determined by comparing the absorption at 
260 nm (DNA) and 280 nm (protein). When the ratio (𝐴bs 260 𝑛m/ 𝐴bs 280 𝑛m) was 
between 1.8 and 2.0 it was considered pure. A ratio of < 1.8 represented a contamination with 
other organic compounds or proteins, while a ratio of > 2.0 indicated an RNA contamination. 
3.3.3 Gateway cloning  
The cDNA of genes of interest contained in Gateway-compatible entry-vectors in were 
obtained from the GPCF, DKFZ and were transferred to the appropriate destination vector 
using the LR reaction according to the manufacturer’s instructions. Briefly, the LR reaction 
mix was made as follows: 
 
Table 3.2- Gateway cloning reaction mix  
Component Volume (µL) 
Entry clone  50-150ng)  1-7 
Destination vector  150ng/μL) 1 
TE Buffer Up to 8µL 
LR Clonase™ II enzyme mix  2 
 
The reaction was incubated at 25°C for 1 hour then stopped by the addition of 1μL proteinase 
K, mixed and incubated at 37°C for 10 minutes. Bacteria was transformed by mixing 1μL of 
the LR reaction then electroporation, followed by the addition of 500μL LB and shaking at 
225-250rpm for 1 hour at 37°C before being spread on an agar plate with the appropriate 
antibiotics and incubated overnight at 37°C. Colonies that grew on the plate were picked, 
grown, DNA was isolated and digested with restriction enzymes to confirm that the insertion 
was successful. Glycerol stocks of the verified constructs were made and stored at -80°C. 
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3.3.4 Polymerase chain reaction (PCR) 
PCR was used to amplify genes of interest for different cloning procedures. The reaction mix 
was composed of the following: 
 
Table 3.3 – Q5 PCR reaction mix  
Component Volume  (µL) 
Q5 reaction buffer 5 
dNTPs 2 
Forward primer 1.25 
Reverse primer 1.25 
DNA 1ng   
Q5® High-Fidelity DNA Polymerase 0.25 
GC enhancer  5 
ddH2O 9.25 
 
 The reactions ran under the following program: 
 
Table 3.4- Parameters set for the PCR program  
Number of cycles Temperature  (°C) Time  (sec) Step 
1 x 98 30   Denaturation 
30x 98 10   Denaturation 
58 30   Annealing 
72 30   Extension 
1x 72 120 Final extension  
 
The PCR product was purified using the QIAquick PCR Purification Kit according to 
manufacturer’s instructions and thereafter either visualized on a 1% agarose gel or used in 
other cloning procedures. 
 
3.3.5 DNA Ligation 
In order to ligate an insert into a vector a ratio of 1:3 was set up as follows and incubated 
overnight at 16°C. 
 
Table 3.5- DNA ligation reaction mix  
Component Volume (µL) 
10x T4 DNA Ligase Buffer 2 
Vector DNA 0.02pmol 
Insert DNA 0.06pmol 
T4 DNA Ligase  400,000U/mL) 1 
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ddH2O up to 20μL 
 
3.3.6 RNA purification 
All mRNA was obtained from cultured cells grown in a 12-24 well format and purified using 
the Rneasy Mini Kit according to manufacturing instructions and the concentration was 
determined using a Nanodrop. 
3.3.7 Reverse Transcription 
In order to perform quantitative PCR, cDNA was generated from extracted RNA. All materials 
were obtained, and procedures followed according to manufacturer’s protocols 
(ThermoFisher Scientific, Waltham, USA). Briefly, the basic master mix for one reaction as 
follows: 
 
Table 3.6- Reverse transcription reaction mix  
Component Volume (µL) 
10x RT buffer 2 
25x dNTP mix  100mM) 0.8 
Random primers 2 
Multiscribe™ Reverse Transcriptase 1 
ddH2O 4.2 
 
10µL of 2X RT master mix was added to 10µL RNA in a PCR tube and mixed by gently 
pipetting up and down. After a brief centrifugation the samples are placed in a thermocycler 
and run under the following program: 
 
Table 3.7- Parameters set for the PCR program  
Temperature (°C) Time (min) 
25  10 
35 120 
85 5 
4 ∞ 
 
3.3.8 Quantitative PCR (qPCR) 
In order to quantify the amount of (reverse transcribed) mRNA transcripts are in a sample 
the following qPCR mix was prepared on ice: 
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Table 3.8- qPCR reaction mix  
Component Volume (µL) 
SsoAdvanced© Universal SYBR® Green 
Supermix 
5 
Forward primer 350nM 
Reverse primer 350nM 
cDNA 3 
Nuclease free ddH2O Up to 10 µL 
 
The samples were mixed thoroughly and pipetted into a 96-well PCR plate in duplicates, 
sealed and run in the CFX96 Touch™ thermocycler under the following program: 
 
Table 3.9- Parameters set for the qPCR program  
Process stage Temperature 
(°C) 
Acquisition 
Mode 
Hold  
(mm:ss) 
Ramp 
Rate  
(°C/s) 
Acquisitions 
per (°C) 
Pre-
incubation 
95 None 05:00 4.4  
Amplification 95 None 00:20 4.4  
60 None 00:15 2.2  
72 None 00:15 4.4  
Melting 
Curve 
95 None 00:05 4.4  
70 None 01:00 2.2  
72 Continuous - - 2 
Cooling 40 None 00:30 1.5  
 
The data obtained was analyzed with the CFX Manager™ Software.  
 
3.3.9 CPO I cloning 
4µL 100pMol of each oligonucleotide was mixed with 32µL annealing buffer (10mM Tris-Cl, 
150mM NaCl pH7.6) and was run in a thermocycler under the following program: 
 
Table 3.10- Parameters set for the PCR program  
Temperature (°C) Time (min) 
95  5 
72 20 
37 20 
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The ligation reaction was set up as follows: 1µL of the vector cleaved with CPOI and 
dephosphorylated was mixed with 1µL of the annealed primers, together with 2µL of 10x T4 
DNA ligase buffer, 1µL T4 DNA ligase(400,000 cohesive end units/ml) and 15µL water. The 
mixture was incubated at room temperature for 40 minutes, 1µL was used to transform 
electrocompetent bacteria before being spread on an agar plate with the appropriate 
antibiotics and incubated overnight at 37°C. Colonies that grew on the plate were picked, 
grown, DNA was isolated and digested with restriction enzymes to confirm that the insertion 
was successful. Glycerol stocks of the verified constructs were made and stored at -80°C. 
3.3.10 QuikChange II Site-Directed Mutagenesis 
The QuikChange II Site-Directed Mutagenesis kit (Agilent technologies) was used to mutate 
single nucleotides or amino acids according to manufacturer’s instructions. Briefly, the 
reaction mix was made as follows: 
Table 3.11- QuikChange II reaction mix  
Component Volume (µL) 
10x reaction buffer 5 
Forward primer 125ng 
Reverse primer 125ng 
dNTP mix 1 
Nuclease free ddH2O Up to 50 µL 
PfuUltra HF DNA Polymerase  (2.5U/µL) 1 
 
The samples were subjected to the following PCR program: 
 
Table 3.12- Parameters set for the PCR program  
Number of cycles Temperature (°C) Time (sec) Step 
1 x 98 30   Denaturation 
12-18x* 98 30 Denaturation 
55 60   Annealing 
68 7-10 min.   Extension 
1x 72 120 Final extension  
*12 cycles for point mutations, 16 for single amino acid changes and 18 for multiple amino acid 
changes. 
 
1µL of Dpn I restriction enzyme (10 U/μl) was added to the reaction to digest the parental 
dsDNA, mixed gently but thoroughly and then spun down and incubated at 37°C for 1 hour. 
1µL of the reaction was used to transform XL-1 Blue supercompetent cells via heat shock 
before being spread on an agar plate with the appropriate antibiotics and incubated 
overnight at 37°C. Colonies that grew on the plate were picked, grown, DNA was isolated and 
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confirmed via sequencing.  Glycerol stocks of the verified constructs were made and stored 
at -80°C. 
3.3.11 Restriction digests 
To check whether a sequence was cloned correctly, restriction digests were performed. A test 
digest consisted of 1x respective buffer, ~1µg DNA, water bringing the total volume up to 
20µL and the restriction enzyme(s). The reactions were then incubated at 37°C for 1 hour 
before analysis on an agarose gel. 
3.3.12 Agarose gel electrophoresis 
1% Agarose gels were used to analyze DNA. This consisted of 1g agarose in 100mL TAE buffer 
with 7μL Ethidium bromide. After the gel polymerized it was placed in the running chamber 
filled with TAE buffer, 6x DNA loading buffer was mixed with the samples and loaded 
alongside a DNA marker (of the appropriate size range). Gels were run at 100V for 30 minutes 
and visualized at 254nm for analysis. In order to purify DNA from bands excised from the 
gels, the QIAquick Gel extraction kit was used according to manufacturer’s instructions 
3.3.13 Transformation of E.coli bacteria 
3.3.13.1 Transformation of E.coli bacteria via electroporation 
Mega X (MXDH10) is an electrocompetent strain of E. coli. To transform this bacterium, a vial 
of frozen cells was thawed on ice and transferred to an electroporation cuvette. 1µL of the 
construct of interest was mixed with the bacteria and the cuvette was placed in the 
electroporator and pulsed at 2.5 kV for 5ms. 0.5mL LB Medium was added to the cells and 
they were shaken at 225-250rpm for 1 hour at 37°C before being spread on an agar plate 
with the appropriate antibiotics and incubated overnight at 37°C. Colonies that grew on the 
plate were picked, grown, DNA isolated and confirmed via sequencing.  Glycerol stocks of the 
verified constructs were made and stored at -80°C. 
3.3.13.2 Transformation of E.coli bacteria via heat shock 
XL-1 Blue supercompetent cells were transformed via heat shock. To do so 1µL of the 
construct of interest was mixed with the cells which were gently swirled and incubated on 
ice for 30 minutes before being subjected to 45 second heat shock pulse at 42°C, then placed 
on ice again for a further 2 minutes. 0.5mL SOC Medium was added to the cells and they were 
shaken at 225-250rpm for 1 hour at 37°C before being spread on an agar plate with the 
appropriate antibiotics and incubated overnight at 37°C. Colonies that grew on the plate were 
picked, grown, DNA isolated and confirmed via sequencing.  Glycerol stocks of the verified 
constructs were made and stored at -80°C. 
3.3.14 Verification of DNA via sequencing 
To determine that the correct DNA sequence was successfully cloned, an aliquot was sent to 
Eurofins, Ebersberg, Germany. Whereby the appropriate sequencing primer was selected. 
The results were analyzed using Clone Manager. 
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3.3.15 Preparation of glycerol stocks 
In order to prepare glycerol stocks for the long-term storage of constructs, 1mL of an 
overnight culture of the construct of interest was mixed in a cryovial with 300μL of pre-
warmed sterile glycerol and stored at -80°C. 
3.4 Protein analysis methods 
3.4.1 Immunofluorescence 
Cells for immunofluorescence were seeded on coverslips in a 12-well plate format. They 
underwent either transfection or infection and were incubated at 37°C 5% CO2. The media 
on the cells was aspirated and they were washed with 1xPBS for 10 minutes. The cells were 
then fixed with 2% PFA for 15 minutes and incubated two times for 10 minutes with 50mM 
Ammonium Chloride to quench artifacts of the dyes, then the cells were incubated with 0.2% 
Triton-X for permeabilization. The cover slips were thereafter washed three times with 
1xPBS and incubated with 1%BSA for 1 hour at 37°C for blocking. The cells were incubated 
with the appropriate primary antibody diluted in blocking buffer for 1 hour at 37°C or 
overnight at 4°C. Then washed three times with 1xPBS and incubated with the corresponding 
Alexa-conjugated antibody (also diluted in blocking buffer) for 1 hour at 37°C. After three 
more washes the coverslips are transferred onto microscopy slides using mounting medium 
and are sealed with nail polish. The slides were thereafter viewed under the Zeiss Cell 
Observer or Olympus confocal microscope. 
3.4.2 Protein concentration determination 
The concentration of the proteins was determined by the comparison to a BSA standard as 
follows: 2µg/ml of BSA was titrated in a 2-fold manner in the first 10 wells of a 96-well plate 
in duplicate followed by a blank. The protein of interest was diluted 3 times in a two-fold 
manner and the Bradford reagent was diluted 1:5 and was added to the plate. The 
concentration of the protein was then measured on the Multiskan Go microplate 
spectrophotometer and protein amounts were adjusted accordingly. 
3.4.3 Dot Blot 
For the analysis of native proteins, a Dot blot was performed. Either a nitrocellulose or PVDF 
membrane (pre-soaked in methanol for activation) were briefly soaked in transfer buffer 
before being placed on top of 3 filter papers on the bottom module of the dot blot apparatus. 
The 96 well top portion of the apparatus was fixed on top of the bottom half, sealed with 
parafilm and connected to a vacuum pump. The pump was switched on and after a few 
minutes 5-10µL of the protein sample was loaded into the wells. After the loading was 
completed, the pump was run for a bit longer to ensure that the sample was pulled through 
efficiently, then the apparatus was disassembled, and the blot was placed in 5% blocking 
milk. After 30 minutes-1 hour the blot was diluted in the appropriate concentration of 
primary antibody diluted in blocking buffer and incubated overnight at 4°C with shaking. The 
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next day the blot was washed with 1xPBS-T (0.03% Tween), three times and then incubated 
with the appropriate HRP-conjugated secondary antibody for 1 hour at room temperature 
with shaking. After three more washing rounds, the blot was incubated with 
chemiluminescent detection reagent and developed using the developing machine. 
3.4.4 SDS-PAGE  
SDS-PAGE was performed to separate proteins according to their molecular weights. The 
cells were harvested in lysis buffer, mixed with 3x SDS loading buffer and were boiled at 95°C 
for 5 minutes. 10-15µL of the samples were added to the SDS-gel set up in the chamber and 
filled with 1x TGS buffer. The stacking gel was run at 80 V for 30min and the resolving gel at 
100- 120 V. 
3.4.5 Western Blot 
If the samples were needed for western blot analyses the SDS gel was transferred by wet blot 
transfer. Blotting pads were soaked in wet blot transfer buffer and placed in the X Cell II™ 
Blot Module. Blotting papers were soaked in the same fashion and placed on the pads, the gel 
was carefully removed from the chamber and placed up-side-down onto the papers and 
smoothened over to remove bubbles. A PVDF membrane, pre-soaked in methanol for 
activation was placed in the transfer buffer, then placed on top of the gel, followed by more 
blotting papers and pads. The chamber was placed into the running chamber and filled on 
the inside with wet blot transfer buffer and on the outside with distilled water. The chamber 
was run at 30V for 1 hour and the resulting membrane was placed in 5% blocking milk. After 
30 minutes-1 hour the blot was diluted in the appropriate concentration of primary antibody 
and incubated overnight at 4°C with shaking. The next day the blot was washed with 1xPBS-
T, three times and then incubated with the appropriate HRP-conjugated secondary antibody 
for 1 hour at room temperature with shaking. After three more washing rounds, the blot was 
incubated with chemiluminescent detection reagent and developed using the developing 
machine. 
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4 Results 
4.1 The intracellular localization of SPOP and SPOPL 
A yeast-2-hybrid screen and TAP-tag experiment previously performed in the lab identified 
the Speckle-type POZ protein (SPOP) as an interaction partner of AAV capsid protein VP1. In 
order to visualize the cellular localization of SPOP, monoclonal antibodies were produced for 
use in an indirect immunofluorescence assay (Figure 4.1a). Across different cells lines, 
endogenous SPOP was expressed in its characteristic speckled pattern in the cell nucleus. The 
Speckle-type POZ protein-like (SPOPL), the paralog of SPOP which bares the same protein 
sequence save for an extra 18 amino acids, also exhibits a speckled pattern but in stark 
contrast to SPOP, SPOPL is localized in endosomes (Figure 4.1b). 
 
 
Figure 4.1 SPOP localizes in the nucleus while SPOPL localizes in endosomes. a. 
Endogenous SPOP was visualized in different cell lines. SPOP is expressed in nuclear speckles. 
b. The localization of SPOP and SPOPL in HeLa cells was visualized. SPOP is present in nuclear 
speckles (stained in red), while SPOPL is localized in endosomes (stained in green). SPOP was 
visualized with LN6 (anti-SPOP mouse monoclonal antibody), SPOPL with polyclonal guinea 
pig serum raised against SPOPL, DAPI (blue) was used to stain the nucleus.  
The co-staining of SPOP and SPOPL shows the contrasting localization. SPOPL (stained in 
green) is expressed outside the nucleus (in endosomes) while SPOP (stained in red) can be 
seen in distinct dots inside the nucleus. It appears that SPOPL is expressed in a much higher 
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level in comparison to SPOP, provided that the antibodies detect both proteins with similar 
sensitivity. This may be due to regulatory role that SPOPL is thought to play on SPOP. 
4.2 SPOP co-localizes with different AAV2 capsid proteins 
As mentioned above, previous experiments identified the interaction of SPOP with AAV2 
capsid protein VP1. In order to visualize this, SPOP was co-stained alongside the AAV2 capsid 
proteins (Figure 4.2).  
 
Figure 4.2 SPOP co-localizes with different capsid proteins. SPOP was visualized 
alongside the overexpressed AAV2 capsid proteins. Top panel shows a construct expressing 
VP1 only (VP2 and 3 start codons are silenced). Middle panel shows a construct expressing 
VP3 only and the lower panel shows a construct expressing the VP2 N-terminus (the region 
between VP2 and VP3). Endogenous SPOP was visualized with LN6 (anti-SPOP antibody), 
VPs were visualized with B1 (top and middle panel) and A69 (lower panel), DAPI was used 
to stain the nucleus. Arrows indicate areas of signal overlap.  
VP1 (upper panel) is expressed ubiquitously throughout the nucleus, however some distinct 
dots can be seen. These appear to overlap with the nuclear speckles in which SPOP is 
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expressed. The VP3 (middle panel) and VP2 N-terminus (lower panel) proteins appear to be 
expressed in a more punctuated pattern in the nucleus. As with VP1, the proteins appear to 
overlap with SPOP speckles, seen by the yellow signal in the overlay (indicated by the 
arrows). Even though co-localization is not direct proof of interaction, it gives an indication 
that there could be several SPOP-binding motifs along the sequences of the AAV2 capsid 
proteins.  
4.3 Investigating the effect of SPOP on AAV2 transduction 
4.3.1 The effects of SPOP knockdown with various siRNAs was inconclusive 
In order to characterize the interaction between SPOP and AAV, at first the influence on 
transduction was investigated. This was done by a protein knockdown using different siRNAs 
targeting SPOP mRNA in two different cell lines, followed by the transduction of AAV2-firefly 
luciferase (Figure 4.3). 
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Figure 4.3 The effects of SPOP knockdown with various siRNAs was inconclusive. HeLa 
and HEK 293TT Cells were transfected with siRNAs against SPOP mRNA (siSPOP1,2,3) or 
SUMO 1 enzyme mRNA (Sae2) as a control, then transduced with AAV2-firefly luciferase 
vectors at a MOI= 103 (see scheme). a. Transduction efficiency when compared to the 
negative control (scr).  b. qPCR analysis of the amount of mRNA after knockdown. Note, data 
displayed represents the mean and standard deviation of 3 independent experiments.  
The amounts of mRNA after the knockdown were quantified using qPCR (Figure 4.3b). 
Different effects were seen between the siRNAs in the various cell lines. According to the 
qPCR, the only conditions where a down regulation of SPOP could be confirmed was by 
siSPOP1 and siSPOP2 treatment in HeLa cells and siSPOP3 in HEK 293TT cells. However, this 
downregulation culminated in opposing effects. The knockdown by siSPOP1 and siSPOP2 in 
HeLa resulted in a 0.3 fold change in transduction, while siSPOP3 caused a 3 fold increase. 
Sae 2 served as a positive control, as its knockdown resulted in a significant increase in 
transduction in HeLa cells and could be verified via qPCR.  
4.3.2 A knockout of SPOP resulted in a 2 fold increase in AAV2 transduction efficiency 
Given the diverging effects seen with the siRNAs, we investigated the consequence of the total 
exclusion of SPOP to the system using CRISPR-Cas9 technology (Figure 4.4). 
I attempted to produce CRISPR-Cas9 knockouts in the lab, with varying levels of success 
(Figure 4.4a). In one clone SPOP was completely knocked out (cl 1a) while the other had 
reduced expression in comparison to the control (cl 1b). The resultant effect was a 2-fold 
increase in AAV2 transduction. However, this effect levelled out over time. 
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Figure 4.4 SPOP has a 2 fold effect on AAV2 transduction efficiency, as confirmed in a 
knockout model. CRISPR-Cas9 knockout cells were transduced with AAV2-firefly luciferase 
vectors and compared to control cells (see scheme). Western blot analysis revealed the status 
SPOP in the clones, using guinea sera raised against SPOP. a. Self-made HEK 293TT Cells with 
clones that have down-regulated protein (SPOP K/O cl. 1b) or complete knockout (SPOP K/O 
cl. 1a) were transduced with MOI= 103. b. Commercially obtained SPOP knockout HeLa were 
transduced with MOI= 104. Note, data displayed represents the mean and standard deviation 
of 3 independent experiments. 
To confirm the above observation, commercially produced SPOP knockout HeLa cells were 
obtained and tested. These cells were less permissive to AAV2, but the 2-fold effect was 
verified, likewise, this also levelled out over time. 
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4.4 Investigating the effect of SPOPL, Cullin 3 and the proteasome on 
AAV2 transduction 
SPOP acts as substrate recognition subunit (SRS), on a Cullin 3 scaffold. The E3-ubiquitin 
ligase complex is involved in the ubiquitination and targeting of proteins primarily to the 
proteasome for degradation. To do so, SPOP forms active homodimers. Nonetheless, the 
pattern of ubiquitination can also alter the consequence for the cargo, e.g. by mediating the 
targeting to different compartments, SPOPL forms less-active heterodimers that are believed 
to regulate SPOP in this manner. For this reason, the role that the other complex factors play 
on the transduction of AAV2 was also investigated.  
4.4.1 SPOPL and Cullin 3 do not affect AAV2 transduction efficiency 
Along with SPOP, Cullin 3 was also identified via the TAP-tag experiments as an interacting 
protein of AAV capsid protein VP1. Thus, the effect on transduction efficiency after a 
downregulation of the protein was investigated (Figure 4.5). 
 
Results 
 
54 
 
Figure 4.5 SPOPL and Cullin 3 have minor effects on AAV2 transduction. HeLa and HEK 
293TT cells were transfected with siRNAs against SPOPL (siSPOPL), Cullin 3 (Cul3) or SUMO 
1 enzyme (Sae2) mRNA as a control, then transduced with AAV2-firefly luciferase vectors at 
a MOI= 103 (see scheme). a. Transduction efficiency when compared to the negative control 
(scr). b. qPCR analysis of the amount of mRNA after knockdown. Note, data displayed 
represents the mean and standard deviation of 3 independent experiments.  
The downregulation of SPOPL and Cullin 3 did not have a significant effect on AAV2 
transduction in both the cells lines (Figure 4.5a). Especially in comparison to knockdown of 
the SUMOylation enzyme Sae2 which resulted in an up to a 3-11-fold increase in transduction 
in HEK 293TT and HeLa cells respectively. Moreover, the knockdown of all proteins could be 
confirmed by a significant reduction of mRNA copies. 
4.4.2 Proteasome inhibition increases AAV2 transduction, even in SPOP-deficient cells 
If the ubiquitination of AAV leads to the degradation, then the inhibition of the proteasome 
should result in increased transduction. This has been previously shown in literature and 
was confirmed in our system (Figure 4.6)[179].  
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Figure 4.6 Proteasome inhibition increases AAV2 transduction even after SPOP 
knockout. Cells were treated with proteasome inhibitors (MG-132 and bortezomib) or 
DMSO as a control and transduced with AAV2-firefly luciferase vectors at MOI= 103 for 4 
hours (see scheme). a. Transduction efficiency in HeLa and HCT cells. b. Transduction 
efficiency in commercially obtained SPOP knockout HeLa and parental HeLa controls. Note, 
data displayed represents the mean and standard deviation of 3 independent experiments.  
The cells exhibited different transduction efficacies, for example HeLa cells were more 
permissive to AAV transduction, and proteasome inhibition had a more pronounced effect in 
comparison to HCT cells. Nonetheless, an 8-fold increase in transduction upon proteasome 
inhibition was observed in these cells (Figure 4.6a). Even between batches of HeLa cells there 
appeared to be differences, the commercially obtained parental HeLa cells only showed a 10-
fold increase upon bortezomib treatment compared to the 28-fold increase in HeLa cells from 
the lab. Surprisingly, there was still an increase in transduction in the absence of SPOP, albeit 
less than that in the parental cells. This points to the involvement of other E3-ubiquitin 
ligases in the restriction of AAV via the proteasome. 
4.4.3 Proteasome and Cul3 complex inhibition increases transduction of AAV2 specifically, 
even in SPOP-deficient cells 
Next, the question beckoned if the restriction was AAV-specific or if this could be seen also 
for other viruses. Therefore, the effect of AAV2 vector transduction was compared to that of 
HPV16 vectors upon inhibition of the proteasome, or of the cullin-3 complex, or both (Figure 
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4.7).
 
Figure 4.7 Proteasome and Cul3 complex inhibition increases transduction of AAV2 
specifically even after SPOP knockout. Parental HeLa cells and SPOP knockout HeLa cells 
were treated with proteasome inhibitors (MG-132 and bortezomib) or cullin 3 complex 
inhibitor (MLN-4924) either with DMSO as a control or in concert; and transduced with 
viruses encoding firefly luciferase for 4 hours (see scheme). a. Transduction efficiency of 
AAV2-firefly luciferase vectors at a MOI= 103. b. Transduction efficiency of HPV-16 firefly 
luciferase vectors at 1:1000. Note, data displayed represents the mean and standard 
deviation of 3 independent experiments. Red lines indicate the AAV-specific effect when 
comparing proteasome + CRL3 inhibition in both cell lines.  
As seen before, inhibition of the proteasome resulted in an increase in transduction. On the 
other hand, the inhibition of the cullin-3 complex did not influence transduction, which is 
consistent with the cullin-3 knockdown experiments (see Figure 4.5). The increment upon 
proteasome inhibition was also seen in the SPOP knockout cells, but 3 times less than in the 
parental cells (see red bars, Figure 4.7a). The effect was confirmed to be AAV-specific (see 
red bars, Figure 4.7b).  
4.5 Investigating the effect of SPOP on stability of incoming capsids  
Given the mild effect that SPOP has on AAV2 transduction, we sought to investigate whether 
the interaction of SPOP and AAV might have a consequence on the stability of the capsids. To 
do this, cells were transduced with AAV2 firefly luciferase vectors and were collected over 
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time to see if there were differences in the presence or absence of SPOP. At first the intact 
capsids were probed over time via dot blot analyses (Figure 4.8). 
 
Figure 4.8 The AAV2 particles are stabilized in the absence of SPOP. Parental cells and 
SPOP knockout cells were transduced with AAV2-firefly luciferase vectors at a MOI= 104. The 
cell lysates were harvested at different timepoints, spotted on a dot blot and capsids were 
visualized with anti-capsid antibody A20. (see scheme). a. Capsid turnover in HeLa cells. b. 
The quantification of capsids in HeLa cells set relative to capsids at 12hours in SPOP K/O 
cells. c. Capsid turnover in HEK 293T cells. d.  The quantification of capsids in HEK 293T cells 
set relative to capsids at 12hours in SPOP K/O cells.  
The number of capsids of the incoming virus should reduce overtime given that the virus 
completes its infection cycle, this steady decrease is seen in the parental cells (see parental 
HeLa, Figure 4.8 a, b). However, the absence of SPOP appeared to stabilize capsids in both 
cell lines. The effect was more pronounced in HEK 293T cells with 2 times more capsids at 
48 hours (Figure 4.8 c, d). The lower capsid amount quantified at 24 hours in the SPOP 
knockout cells is due to a blotting artefact. 
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Next we investigated if the stability seen on a protein level could also be visualized via 
indirect immunofluorescence. Consequently, cells were infected as above and stained for 
capsids at different timepoints (Figure 4.9). 
 
Figure 4.9 The AAV2 particles persist for longer in the absence of SPOP. Parental and 
SPOP knockout HeLa cells were transduced with AAV2-firefly luciferase vectors at a MOI= 
105. The cells were fixed and stained for capsids using the anti-capsid antibody A20 (see 
scheme). a. Capsids in the parental (upper panel) and SPOP knockout HeLa cells (lower 
panel) are visualized. b. The capsids from 6 different fields of view, were quantified and set 
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relative to capsids at 12 hours in SPOP K/O HeLa cells. Arrows indicate a point accumulation 
of capsids; arrowheads indicate capsids that are still visible after 48 hours.  
From 12 hours on in the parental cells the capsids are seen to accumulate close to the nucleus 
(arrows, Figure 4.9a). However, this accumulation could not be seen in the SPOP knockout 
cells.  Moreover, the number of capsids reduced over time in the parental cells but appeared 
to be stabilized in the absence of SPOP and could be seen at 72 hours (arrowheads, Figure 
4.9a). A quantification of capsids from different sections of the microscopy slides revealed 
that there were 3 times as many capsid-specific signals in the SPOP knockout cells at 48 hours 
and 2 times as many after 72 hours. Hence, the interaction with SPOP appeared to reduce the 
stability of incoming capsids. 
4.6 Investigating the effect of SPOP on stability of newly synthesized 
capsid proteins 
Given the interaction with SPOP affected the stability of incoming capsids, we wanted to 
investigate whether the interaction also influenced newly synthesized capsids proteins and 
intact capsids. The assembly activating protein (AAP) plays a crucial role in most AAV 
serotypes. It is thought to act as a scaffold for the assembly of capsids[23]. Therefore, we 
explored the role of SPOP on newly synthesized capsid proteins before assembly (by 
expressing AAV2 WT constructs that lack AAP), after assembly (by supplying AAP in trans) 
and with the addition of SPOP. 
4.6.1 SPOP regulates stability of newly assembled capsids 
As mentioned above AAV2 capsids only assemble in the presence of AAP. Therefore, AAP was 
supplied in trans and the assembly capabilities in the presence and absence of SPOP were 
evaluated (Figure 4.10). 
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Figure 4.10 SPOP affects the stability of newly assembled capsids. The state of the de 
novo synthesized capsids was analysed by dot blot and quantified relative to capsids of 
pTAVORF2stopB + AAP and pTAVORF1cm + AAP in the SPOP K/O cells, respectively. The 
capsid proteins were expressed from constructs that do not contain AAP either alone(Ø) or 
in trans with a construct expressing AAP (+AAP) or SPOP (+SPOP). a. Dot blot displaying the 
expression from a construct that has a stop in the second ORF that expresses AAP 
(pTAVORF2stopB). b. Dot blot displaying the expression from a construct that has been 
codon modified and does not contain the second ORF expressing AAP (pTAVORF1cm). A20 
antibody visualized intact capsids. The results displayed are representative of three 
experimental replicates.  
As seen with the stability of incoming capsids, SPOP is also able to regulate newly synthesized 
capsids. An evaluation of the dot blot shows that 2-fold more capsids are produced in the 
absence of SPOP with either construct. This eludes to the ability of SPOP to restrict different 
parts of the AAV life cycle.  
4.6.2 SPOP regulates newly synthesized unassembled capsid proteins 
The effect of SPOP on the state of unassembled capsid proteins was also evaluated. Since AAP 
assembles capsids, we evaluated the state of unassembled capsid proteins by using the same 
vector that had a stop in the AAP sequence (pTAVORF2stopB) as above (Figure 4.11). 
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Figure 4.11 SPOP affects the stability of unassembled capsid proteins. The state of the 
capsid proteins was analysed by western blot (a) and via dot blot (b); and quantified relative 
to VP2 of pTAVORF2stopB + AAP in the SPOP K/O cells (a); and relative to the unassembled 
capsids of pTAVORF2stopB Ø in the SPOP K/O cells (b), respectively. The capsid proteins 
were expressed either alone (Ø) or in trans with a construct expressing AAP (+AAP) or SPOP 
(+SPOP). B1 antibody was used to visualize unassembled VP. The black arrows indicate the 
differences in the expression of unassembled VP in the presence or absence of endogenous 
SPOP. The results displayed are representative of three experimental replicates.  
According to the western blot, the absence of SPOP also appeared to stabilize the 
unassembled capsid proteins- seen by the 3-fold increase in absence of AAP (Ø) (Figure 
4.11a). The same phenomenon was confirmed via the dot blot with a 3-fold increase in 
comparison to the parental cells (Figure 4.11b). Moreover, the re-expression of SPOP in the 
knockout cells (via transfection) appeared to reduce the stability of the unassembled capsid 
proteins (0.8-0.9 fold change). The overexpression of SPOP in the parental cells appeared to 
partially stabilize the VP protein. This was seen by the appearance of VP3 in the western blot 
analysis (Figure 4.11a) and the increased signal in the dot blot (Figure 4.11b). The 
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overexpression of one protein could alter the molecular composition of a complex, possibly 
leading to its inactivation. This shall be discussed in more detail later. 
Furthermore, there was a 3 fold higher expression of capsids proteins (+AAP) in the SPOP 
knockout cells which supports the effect of SPOP on the intact capsids (see Figure 4.10).  
The effects seen above were verified with the other construct that did not contain AAP 
(Figure 4.12). 
 
Figure 4.12 SPOP affects the stability of unassembled capsid proteins. The state of the 
capsid proteins was analysed by western blot (a) and via dot blot (b); and quantified relative 
to VP2 of pTAVORF1cm + AAP in the SPOP K/O cells (a); and relative to the unassembled 
capsids of pTAVORF1cm Ø in the SPOP KO cells (b), respectively. The capsid proteins were 
expressed either alone(Ø) or in trans with a construct expressing AAP (+AAP) or SPOP 
(+SPOP). B1 antibody was used to visualize unassembled VP. The black arrows indicate the 
differences in the expression of unassembled VP in the presence or absence of endogenous 
SPOP. The results displayed are representative of three experimental replicates.  
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Both constructs had different levels of expression but showed a similar trend. The absence 
of SPOP was able to stabilize unassembled capsid proteins, with a 52-fold increase seen in 
the dot blot (Figure 4.12b). The re-expression of SPOP in the knockout cells (via transfection) 
had a destabilizing effect on the unassembled capsid proteins seen with the 0.8-fold change 
in the western blot (Figure 4.12a) and the 0.7-fold change in the dot blot. However, the effect 
of SPOP overexpression in the parental cells had opposing effects in the western blot and dot 
blot assays. 
Again, the effect of SPOP on assembled capsids is seen as 1.4-fold more capsid proteins were 
expressed in the SPOP knockout cells upon trans expression of AAP. 
4.6.3 SPOP rescue via lentiviral infection does not fully restore the parental cell phenotype 
Although the transfection of SPOP in the knockout cells had a destabilizing effect on 
unassembled VP, the expression varied and did not fully reach wild type levels, therefore I 
restored SPOP expression through the lentiviral infection of the SPOP knockout cells. The 
restoration of the SPOP protein was verified via western blot and the cells were used in the 
same assay as described above. The question was whether SPOP rescue would to restore the 
phenotype seen in the parental cells (Figure 4.13).  
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Figure 4.13 The restoration of SPOP destabilizes unassembled capsid proteins, but not 
to wild-type levels. The state of the capsid proteins in the presence or absence of SPOP was 
analysed by western blot. The capsid proteins were expressed via two different constructs 
that do not contain AAP (pTAVORF2stopB and pTAVORF1cm) either alone(Ø) or in trans 
with a construct expressing AAP (+AAP). B1 was used to visualize the VP proteins. The upper 
panel of graphs quantify the VP2 bands relative to PTAVORF2stopB + AAP and pTAVORF1cm 
+ AAP, respectively. The graph in the lower panel quantifies the amount of SPOP relative to 
the levels in the parental cells. Anti-SPOP antibody was used to visualize SPOP. P1B and P2A 
were SPOP knockout cells infected with lentiviruses that encoded for SPOP, thus restoring 
the expression of the protein (see SPOP western blot and quantification). The results 
displayed are representative of three experimental replicates.  
The restoration of SPOP was clearly visible in both clones (P1B and P2A, see SPOP western 
blot) and resulted in similar effects. The SPOP rescue was able to destabilize the unassembled 
capsid proteins in all cases (0.5-0.9 fold change), as seen previously via transfection, except 
for the 1.2-fold increase seen upon expression from the pTAVORF2stopB construct in the P2A 
cells. A quantification of the SPOP amounts (graph in the lower panel) revealed that the 
rescue cells had twice as much SPOP as the parental cells. One would expect that this would 
cause double the destabilization, however it was not able to reach the levels observed in the 
parental levels. In fact, in these cells the unassembled capsid proteins (Ø) were still stabilized 
to a higher extent than that seen in the parental cells. i.e. 9-13 times more for the 
pTAVORF2stopB construct and 1.3-2 times more for the pTAVORF1cm construct.  
There was also a reduction in the stability of the assembled capsids (+AAP). However, in 
contrast to unassembled capsids, expression from the pTAVORF1cm construct was able to 
restore the intact capsid expression back to wild-type levels (Figure 4.13).  
These different observations led us to question the functionality of the restored SPOP. 
Therefore, in order to probe this, we evaluated the endogenous levels of other SPOP 
substrates, in the parental cells, knockout cells and upon restoration in both HeLa and HEK 
293T cells (Figure 4.14). 
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Figure 4.14 Analyses of SPOP binding substrate levels. The levels of endogenous SPOP 
binding substrates- DAXX, c-myc, SRC3 and BRD4 were evaluated via western blot and 
quantified relative to the levels of the proteins in the SPOP knockout HeLa or HEK 293T cells, 
respectively.  
In general, a knockout of SPOP resulted in an increase of substrate levels in both HeLa and 
HEK 293T cells, however this was more evident in the HeLa cells with up to 3-fold increases 
of c-myc and BRD4. These effects were SPOP-specific given the equal actin signals. The 
differences in baseline expression could be due to the tissue origin, given that HeLa are from 
the cervix while HEK 293T are from the kidney. Nevertheless, the amounts of the DAXX and 
c-myc increased after SPOP knockout and a restoration of SPOP lead to a downregulation, as 
seen with the unassembled capsid proteins. Interestingly, for these two proteins, the 
amounts reduced to even lower levels than those seen in the parental cells. The restoration 
of SPOP had no effect on SRC3 expression and increased BRD4 expression (however this was 
only 1.2-fold). 
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4.6.4 The effect of SPOP on newly synthesized unassembled capsid proteins can be 
visualized 
As for the incoming capsids, next we checked if the increase in stability seen on a protein 
level could also be visualized via indirect immunofluorescence. Therefore, newly synthesized 
capsid proteins were produced and stained (Figure 4.15). 
 
Figure 4.15 The newly synthesized capsid protein stabilization in the absence of SPOP 
can be visualized. The state of newly synthesized capsids proteins in the presence or 
absence of SPOP was analysed by immunofluorescence (see scheme). The capsid proteins 
were expressed via a construct with all capsid proteins intact, including AAP (pTAV2.0), or 
two different constructs that do not contain AAP (pTAVORF2stopB and pTAVORF1cm). A20 
antibody was used to visualize intact capsids, B1 antibody was used to visualize unassembled 
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capsid proteins and Alexa 594 was used as a secondary antibody. Confocal images were taken 
at 60x magnification.  
The pTAV2.0 construct contains the wildtype AAV2 genome, with rep, cap and AAP. The 
accumulation of intact capsids was much higher in SPOP knockout cells compared to the 
parental cells (top panel, Figure 4.15). This difference was not obvious with expression via 
the other two vectors with AAP supplied in trans. The expression and stabilization of 
unassembled capsid proteins in absence of SPOP was most apparent, seen by the higher 
signal intensity in the knockout cells compared to the parental cells (compare the 3rd and 4th 
column, Figure 4.15). This was highest for the expression of capsid proteins via the 
pTAVORF2stopB construct. Furthermore, the immunofluorescence result was consistent 
with the western blot and dot blot data where 2-3 fold higher protein accumulation is seen 
in the knockout cells. The unassembled capsid proteins appear to be majorly located in the 
nucleus, but also present in the cytoplasm. 
A closer look into the knockout cells revealed the stabilization of the capsid proteins, 
expressed in a punctuated pattern in the cell nucleus (see insert, Figure 4.16). 
 
Figure 4.16 Absence of SPOP results in the stabilization of unassembled capsid 
proteins in nuclear clusters. The state of unassembled capsids proteins in the presence or 
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absence of SPOP was analysed by immunofluorescence. The capsid proteins were expressed 
via two different constructs that do not contain AAP (pTAVORF2stopB and pTAVORF1cm). 
B1 antibody was used to visualize unassembled capsid proteins and Alexa 594 was used as a 
secondary antibody. The insert is displayed on the right.  
Although the unassembled capsid proteins were expressed in the nucleus and the cytoplasm, 
the accumulations were only observed in the nucleus of the SPOP knock out cells. Which 
would mean that with functional SPOP, these proteins would be degraded soon after 
production. This is also seen in the dot blot and western blot assays whereby there is less 
unassembled VP in the parental cells, compared to the knockouts.  
The nucleolus is the site of capsid assembly; however, these clusters appear to be in the 
nucleoplasm and not in the nucleoli, though this would need confirmation with co-staining 
of a nucleoli marker. PML has been identified as a restriction factor for AAV, thus we sought 
to find out if the accumulation of the unassembled capsid proteins was in the PML nuclear 
bodies (Figure 4.17). Nevertheless, a co-staining revealed that the capsid proteins 
accumulated outside the PML bodies (see insert, Figure 4.17). 
 
Figure 4.17 Stabilized unassembled capsid proteins do not accumulate in the PML 
bodies. The compartment in which the unassembled capsids proteins gather was 
investigated. The capsid proteins were expressed with pTAVORF2stopB, that does not 
contain AAP. B1 mouse antibody was used to visualize unassembled capsid proteins, Alexa 
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594 labelled anti-mouse was used as a secondary antibody. PML was stained with an anti-
PML rabbit antibody and Alexa 488 labelled anti-rabbit, was used as a secondary antibody. 
DAPI was used to stain the nucleus. The insert is displayed on the right.  
4.7 Investigating the effect of Cullin 3 and the proteasome on newly 
synthesized capsid proteins 
4.7.1 Cullin has a minor effect on the stability of newly synthesized capsid proteins 
Cullin 3 was identified as an interacting factor of AAV via the previously performed TAP tag 
experiments. Given that it acts as the scaffold for SPOP, but had no effect on incoming capsids, 
the role it plays on the stability of newly synthesized capsid proteins before assembly (by 
expressing AAV2 WT constructs that lacked AAP), after assembly (by supplying AAP in trans) 
and with the addition of SPOP was investigated in cells that had down regulated Cullin 3 
(Figure 4.18). 
 
Figure 4.18 Cullin 3 has a minor effect the stability of newly synthesized unassembled 
capsid proteins. The state of the capsid proteins expressed in the cells with down regulated 
Cullin 3 was analysed by western blot and quantified relative to VP3 of pTAVORF2stopB + 
AAP (a) and pTAVORF1cm + AAP (b), respectively. The capsid proteins were expressed via 
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constructs that do not contain AAP either alone(Ø) or in trans with a construct expressing 
AAP (+AAP) or SPOP (+SPOP). a. Western blot and quantification of capsid proteins 
expressed from pTAVORF2stopB. b. Western blot and quantification of capsid proteins 
expressed from pTAVORF1cm. B1 was used to visualize the VP proteins. The results 
displayed are representative of three experimental replicates.  
Unlike with SPOP, unassembled capsid proteins (Ø) were affected to a much minor extent by 
the lack of Cullin 3. i.e. a 1.1-1.6 fold change compared to a 2-10 fold observed in the absence 
of SPOP. In addition, the lack of Cullin 3 appeared to cause a decrease in the number of intact 
capsids (+AAP). In line with the parental cells, the over expression of SPOP appeared to cause 
some stabilization of the capsid proteins. 
4.7.2 Proteasome inhibition stabilizes newly synthesized capsid proteins 
If the mode of AAV restriction via SPOP is exclusively through the proteasome, then it would 
be expected that its inhibition in the parental cells would culminate in the same effect as that 
seen in the absence of SPOP. To test this, newly synthesized capsids were expressed in 
presence of proteasome inhibitor and probed for changes in stability via western blot (Figure 
4.19 and 4.20). 
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Figure 4.19 Proteasome inhibition stabilizes unassembled capsid proteins. The state of 
the capsid proteins was analysed by western blot and quantified relative to VP3 of 
pTAVORF2stopB + AAP in the SPOP K/O cells, under the presence or absence of proteasome 
inhibitor (bortezomib). The capsid proteins were expressed from pTAVORF2stopB that does 
not contain AAP either alone(Ø) or in trans with a construct expressing AAP (+AAP) or SPOP 
(+SPOP). B1 was used to visualize the VP proteins while the anti-SPOP antibody was used to 
visualize SPOP. Lower panels display blots with shorter exposure times. The black arrows 
indicate the differences in the expression of unassembled VP. The results displayed are 
representative of three experimental replicates.  
Looking at the parental cells, proteasomal inhibition appeared to also stabilize the 
unassembled capsid proteins- seen by the 9-fold increase when capsid proteins were 
expressed without AAP (Ø). However, the SPOP effect on the stabilization was stronger, i.e. 
12-fold. Interestingly, proteasome inhibition appeared to cause a minor 0.9-fold change in 
the amount of unassembled VP in the SPOP knock out cells. Furthermore, proteasome 
inhibition appeared to reduce the stability of intact capsids (+AAP) in both cell lines (Figure 
4.19). 
The results were verified by looking at the other construct that does not contain AAP, 
pTAVORF1cm (Figure 4.20). 
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Figure 4.20 Proteasome inhibition stabilizes unassembled capsid proteins. The state of 
the capsid proteins was analysed by western blot and quantified relative to VP3 of 
pTAVORF1cm + AAP in the SPOP K/O cells, under the presence or absence of proteasome 
inhibitor (bortezomib). The capsid proteins were expressed from pTAVORF1cm that does 
not contain the AAP ORF either alone (Ø) or in trans with a construct expressing AAP (+AAP) 
or SPOP (+SPOP). B1 was used to visualize the VP proteins while the anti-SPOP antibody was 
used to visualize SPOP. Lower panels display blots with shorter exposure times. The black 
arrows indicate the differences in the expression of unassembled VP. The results displayed 
are representative of three experimental replicates.  
The e73ffect of proteasome inhibition on unassembled capsid proteins expressed from the 
pTAVORF1cm construct, paints a comparable picture. In that, bortezomib treatment in the 
parental cells caused a 1.3-fold increase when capsid proteins were expressed without AAP 
(Ø). However, the effect of SPOP knock was similar to proteasome inhibition, i.e. 1.2 vs 1.3 
fold, respectively. In addition, proteasome inhibition did not affect the stability of 
unassembled VP in the SPOP knock out cells. As seen above, bortezomib treatment reduced 
the stability of intact capsids (+AAP) in both cell lines (Figure 4.19 and 4.20).    
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5 Discussion 
5.1 The localization of SPOP, SPOPL and AAV2 capsid proteins 
Previously performed tandem affinity purification and yeast 2 hybrid screens identified the 
speckle-type POZ protein (SPOP) as a putatve interaction partner of AAV capsid protein VP1 
[178]. In order to characterize and validate this interaction, first the localization patterns of 
the individual host factors were investigated. SPOP and its paralog-SPOPL share ~80% 
sequence homology, are both characterized by a speckled pattern, however they display 
distinct differences in localization within the cell (Figure 4.1b). SPOP is localized in distinct 
nuclear speckles while SPOPL is localized in the endosomes. The extra 18 amino acid 
sequence in the BACK domain of SPOPL is thought to confer this difference in cellular 
localization [180]. SPOPL is thought to regulate SPOP, as SPOP-SPOPL heterodimers are less 
active than SPOP-SPOP homodimers.  
The AAV2 capsid sequences appear to contain multiple putative SPOP binding sites (SBSs), 
hinted by the co-localization of SPOP with different capsid proteins. This is a common feature 
of SPOP substrates, in humans the death-domain-associated protein (DAXX) has been shown 
to contain multiple SBSs and in drosophila, the transcription factor- Ci and MAPK 
phosphatase-Puc also contain multiple SBSs for the SPOP ortholog HIB/Roadkill [148], [181], 
[182]. AAV capsid protein VP2 N-terminus contains a PDSSS amino acid stretch that shares 
the same characteristics as the originally proposed SPOP binding consensus (SBC) of φ-π-S-
S/T-S/T (φ-nonpolar; π-polar) [139]. According to the recently proposed less stringent SBC- 
φ-π-S-π-π -after Pdx1 was found to bind with SPOP- AHSQS in VP1,2 and 3 and FHSSY in VP1 
and 2 would also qualify as SBSs and would be consistent with the pattern observed in Figure 
4.2 [153]. Further mutational analyses and pull-down assays could confirm this.  
5.2 Investigating the effect of SPOP, SPOPL, Cullin 3 and the proteasome 
on incoming AAV2 capsids 
To investigate the effect of the different factors on AAV2 vector transduction, at first RNAi 
methods using siRNAs targeting the mRNAs of interest were employed, followed by a 
transduction assay with AAV2 firefly luciferase vectors. A down regulation of mRNA copies, 
verified via qPCR gave an indication of knockdown success. The varying effects seen with 
SPOP knockdown through the different siRNAs could either be seen as the sum total of the 
divergent effects -which would be equivalent to the phenotype observed in the knockouts- 
or could be an off target effect of the siRNAs (Figure 4.3). In a previous study using the same 
set of siRNAs, siSPOP1 also managed to greatly reduce infection of influenza A virus (IAV) in 
A549 cells, while siSPOP2 little effect. However, in HeLa cells siSPOP2 managed to reduce 
infection effectively and a qPCR confirmed a reduction of transcripts. These variable effects 
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could either point towards differences in cell-type specificity or give further evidence to the 
off target effects of the siRNAs [180].  
A blast search of the siRNA sequences revealed that the siSPOP3 sequence has 80% homology 
to the ATP binding cassette subfamily A member 13 (ABCA13). The ATP-binding cassette 
(ABC) transporters are transmembrane-spanning proteins that are involved in the transport 
of different molecules. Although no relation between AAV and the ABCs have been made so 
far, defects in ABCA (along with other subfamilies) have been associated with Hepatitis C 
virus (HCV), though the exact mechanisms are not yet fully understood [183], [184]. Perhaps 
this could also play a role in AAV, culminating in the 3 fold increase seen with siSPOP3 
treatment.  
The knockout of SPOP via CRISPR-cas9 technology provided a scenario whereby the effects 
of the specific elimination of SPOP could be studied (Figure 4.4). This revealed a 2 fold 
increase in transduction. The moderate increment hints at the possible involvement of other 
players in the ubiquitin proteasome system in the restriction of AAV transduction. For 
example a recent study found that the Ring Finger Protein 121 (RNF121), a factor that was 
identified in the same haploid screen as the universal receptor AAVR, is an essential E3-ligase 
in AAV transduction [10], [185]. In RNF121 knockout cells, transduction of AAV1, 2, 6 and 9 
was significantly reduced and this was independent of vector dose or cell line. In addition, an 
overexpression of RNF121 could restore the transduction [185]. The observation that the 
SPOP-effect levelled overtime in both scenarios with the self-made knockouts and the 
commercially obtained ones, points towards the intrinsic ability of the cell to restrict 
incoming virus via alternative pathways, especially if the SPOP- CRL3 is not the sole pathway 
that mediates the ubiquitination and degradation of capsids. 
If SPOP is not essential in regulating transduction, then the same would hold true for SPOPL 
and Cullin 3 (Figure 4.5). One would expect a similar increase with Cul3 knockdown as seen 
with SPOP since it acts as the scaffold. However, Cul3 binds to BTB proteins in general and 
~180 are encoded in the human genome. BTBs are involved in a range of functions such as 
chromatin remodelling and transcriptional regulation, oxidative stress regulation and vesicle 
trafficking, just to name a few [137], [186], [187]. A down regulation of the above mentioned 
RNF121, decreases AAV transduction, therefore it is plausible that the phenotype observed 
in this study is a sum of effects of CRL3s with different BTB proteins. SPOPL is thought to be 
a regulator of SPOP, that forms less active SPOP-SPOPL CRL3s [188]. Given that a mild effect 
is seen with SPOP and that SPOPL acts as a negative regulator, the lack of an effect of SPOPL 
on transduction is expected.  
Proteasome inhibition has previously been shown to increase AAV transduction [179]. 
Although the exact mechanism is poorly understood, it is thought that the accumulation of 
ubiquitinated capsids form a conducive environment for the late stages of transduction [179].  
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Proteasome inhibitor treatment was able to increase transduction in all cell lines used in this 
study (Figure 4.6). The differences observed between HeLa and HCT 116 cells is a reflection 
of cell-type specific permissiveness to AAV2 infection (Figure 4.6a). HeLa cells are regarded 
as highly permissive to AAV, as evidence of AAV2 cytoplamic transport was largely obtained 
in experiments using HeLa cells, [53], [189]. HCT116 cells have been used to a lower extent, 
while other colon-derived cell lines such as Caco-2 cells show much lower levels of 
permissiveness [190]. Differences are brought about by the receptors and co-receptors that 
are present on the cell surface and the roles that they play on AAV entry. A study looking into 
the best serotypes for the small intestine and the colon revealed that AAV4, 7, 8, 9, and 10 
transduce with cells with higher efficiency [191].   
A further difference is observed between HeLa batches, denoted by the variation in 
transduction efficiency and the boost upon proteasomal inhibition, i.e a 28-fold increase in 
HeLa cells from the lab stocks vs the 10-fold increase in commercially obtained HeLa cells 
(parental). A study of different batches of HeLa cells found that there were stark differences 
in genomic and transcriptomic profiles. Some cells gained and others lost genomic material, 
causing major differences in basal gene expression [192]. Therefore, since the HeLa cells 
came from different sources, it it plausible that they harbour differences in genetic variation 
in comparison to each other. However, since the SPOP knockout cells were derived from the 
commercially obtained parental cells, they serve as the best comparison for differences in 
phenotype as a result of the loss of SPOP function. 
If the SPOP-CRL3 complex was the sole machinery that restricted AAV infection via 
proteasomal targeting, then it would be expected that there would be no difference between 
a disruption of SPOP (via knockout) or proteasomal inhibition. However, there was still an 
observable effect after treatment with PIs in the SPOP knockout cells. Even though this effect 
was remarkably lower (4-fold, as compared to 10-fold in parental cells), it gives further 
evidence that along with the SPOP-CRL3 complex, there is other ubiquitin-conjugation 
machinery involved in restricting AAV transduction.  
Neddylation is a process required for cullin activation. It is exerted by the binding of Nedd8 
(a ubiquitin-like protein) to a lysine in the c-terminal domain that triggers a conformational 
change causing the RING domain to free up, thereby reducing the distance between the active 
site of the E2 enzyme and the lysine on the target. Nedd8 additionally acts by recruiting the 
E2 enzyme to cullin [130], [193]. MLN-4924 inhibits neddylation and thus the activation of 
Cul3 [194]. MLN-4924 treatment did not affect AAV2 transduction efficiency, which is 
consistent with the lacking effect of knocking down Cul3 on AAV transduction (Figure 4.7). 
However, the combined treatment with proteasome inhibitors was able to boost 
transduction, with the highest increase seen with ‘Bortezomib + MLN-4924’ in the parental 
cells. The SPOP knockout cells still exhibited an increase upon combined treatment, albeit to 
a lesser extent, as previously seen with proteasome treatment alone. For the ‘Bortezomib + 
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MLN-4924’ combined treatment in the context of HPV 16, no increase to transduction was 
observed in both the parental and SPOP knockout cells (compare red lines in Figure 4.7). This 
confirmed that the aforementioned effects were specific to AAV2 transduction. 
Next, the effect of SPOP on the stability of the incoming capsids was evaluated. In the absence 
of SPOP, the incoming capsids showed up to 3-fold higher stability according to the results of 
the dotblot assay (Figure 4.8) and the immunofluorescence analysis (Figure 4.9). These 
experiments give evidence to the mechanism in which SPOP is able to restrict AAV 
transduction, i.e through the ubiquitination and subsequent degradation via the proteasome. 
This is also consistent when looking at the protein accumulation of the other SPOP substrates 
(Figure 4.14), whereby the absence of SPOP increased their levels up to 3-fold when 
compared to baseline levels in the parental cells. The variation seen between the substrates 
could be a result of differences in cell-type specific expression in different tissues. The 
mechanisms in which SPOP binds and acts on other endogenous substrates- DAXX, c-myc, 
SRC3 and BRD4 have been well characterized.  
The direct interaction between DAXX and SPOP was proven via immunoprecipitation and 
shown that the interaction was required for proteasomal degradation [148]. This was 
demonstrated by showing that upon expression of SPOP N- or C- terminal mutants, or by 
proteasome inhibition, DAXX was stabilized. Furthermore, in an in vitro ubiquitination assay 
WT SPOP was required to ubiquitinate DAXX and the expression of the same SPOP mutants 
resulted in little to no ubiquitination of DAXX [148]. SPOPs ability to interact with and 
facilitate the ubiquitination and degradation of the transcription factor (c-myc) was also 
proven using similar techniques. In this case they showed that SPOP-F102C and SPOP-F133V, 
which had alterations in the substrate binding pocket, significantly reduced the amount of 
ubiquitinated c-myc. In addition, the use of cyclohexamide to inhibit new protein synthesis 
together with doxycyclin-induction of SPOP, was able to reduce the half-life of c-myc from 
~50 min to ~25 min [195]. For the steroid receptor co-activator-3 (SRC3), SPOP was proven 
to interact depending on the phosphorylation of the S101/S102. By using a combined shRNA 
and chase experiment, in vitro ubiquitination and employing SRC3 phosphorylation deficient 
mutants; it was proven that SPOP mediates the polyubiquitination and degradation of SRC3 
[158]. Finally, BRD4 which is a member of the bromodomain family involved in epigenetic 
reading of lysine acetylation, was identified as in interaction partner in a yeast-2-hybrid 
screen with full length SPOP as bait. The aforementioned experiments were subsequently 
carried out and SPOP was shown to specifically ubiquitinate and degrade BRD4 [196], [197]. 
The results of this study give strong indications that SPOP acts in a similar manner on 
incoming AAV capsids. A capsid pull down after infection in the different cell lines and an 
inspection of the ubiquitination status, would provide a more concrete picture to link SPOP 
to the capsid ubiquitination. It would be expected that in the absence of SPOP the capsids 
would exhibit less ubiquitination.  
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5.3 Investigating the effect of SPOP, Cullin 3 and the proteasome on 
newly synthesized capsid proteins 
The same phenomenon is seen on newly synthesized capsids whereby the absence of SPOP 
led to 2-fold higher production of capsids (Figure 4.10). In a study characterizing the post 
translational modifications of AAV1-rh10, Mary and colleagues highlighted that the 
environment in the producer cell line may affect the kind of post translational modifications 
that the virus receives, rather than solely being affected upon entry/during infection [171]. 
As hypothesized above, SPOP regulates new capsids via ubiquitination and subsequent 
proteasomal degradation. In vitro ubiquitination assays as performed for the other SPOP 
substrates would be able to provide more information on this restriction. These results also 
indicate the ability of SPOP to regulate different parts of the AAV life cycle.  
However, given that this is a fold lower than the restriction seen for incoming capsids, it is 
also conceivable that AAV/Ad proteins co-expressed could be using the SPOP-SPOPL 
machinery to alter the ubiquitination signal on the newly synthesized capsids, for other non-
proteasomal consequences such as trafficking to the cytoplasm for release. For example, 
E4ORF6 of Adenovirus 5 which is involved in the DNA replication of AAV5 (thus encoded in 
the helper plasmid that is supplied in trans), has been shown to form an E3-ubiquitin ligase 
complex that degrades de novo AAV capsids, but the VA RNA (also encoded in the helper 
plasmid) is able to overcome these effects, in order to achieve overall efficient production of 
AAV5 [198]. In addition, other viruses such as coxsackie, herpes and poxviruses also hijack 
the host cell ubiquitin machinery in their viral replication, transcription, and late stage 
lytic/latent regulation (reviewed in [199]). This provides a picture of the complex host-viral 
interactions that might be exploited by the virus for its own benefit. 
Apart from the effect of SPOP on assembled capsids, there appeared to be another function 
of the SPOP interaction with newly synthesized unassembled capsid proteins (Figure 4.11-
12 & 4.15-17). These results are consistent with the previous observation via a yeast-2-
hybrid screen and a TAP tag experiment that SPOP interacts with the AAV capsid protein VP1. 
It is evident from the western blot and dot blot assays that SPOP restricts unassembled capsid 
proteins via facilitating their degradation. This is particularly exemplified by the 52-fold 
increase in unassembled VP in the SPOP knockout cells compared to the parental controls 
(Figure 4.12b). The differences seen between the constructs could be attributed to the fact 
that pTAVorfStopB still encodes for a bit of AAP, which might have an effect on the capsid 
proteins.  
The stabilization of VP proteins could be vizualized distinctly as the capsid proteins formed 
a punctuated pattern in the nucleus of the cells where AAV transcription and packaging takes 
place [200] (Figure 4.16). Early experiments on the subcellular compartmentalization of 
AAV2 assembly, revealed a similar punctuated pattern of VP1 and VP2 in the nucleus while 
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VP3 was equally distributed between the nucleus and the cytoplasm. In the same study they 
identified that the capsid proteins colocalized with Rep proteins and AAV2 DNA in these 
nuclear clusters [200]. It is therefore plausible that the newly synthesized capsid proteins 
are stabilized in the nucleoplasm when neither AAP is available to facilitate assembly, nor is 
SPOP present to ubiquitinate and target them to the proteasome for degradation. 
The Mittag group postulated that SPOP migrates to form liquid bodies (membrane-less 
organelles) with its substrates inside the nucleus. These bodies contain high-order SPOP 
complexes, increasing the concentration of SPOP-CRL3 players, thus thought to facilitate 
substrate  ubiquitination [151]. A recent study by the same group was able to confirm their 
theory by showing that SPOP phase separates with DAXX in vitro and leaves its nuclear 
speckles to colocalize with DAXX in so called SPOP/DAXX bodies in cells [152]. This gives 
another possible explanation of the nuclear clusters observed, i.e unassembled VP proteins 
that serve as a substrate for SPOP are localized in liquid bodies, awaiting interaction with 
SPOP leading to the subsequent degradation. In addition, the aforementioned study showed 
that these liquid bodies did not co-localize with the nucleoli, polycomb bodies, Cajal bodies, 
or PML bodies [151]. A co-staining with PML in this study is consistent with that finding 
(Figure 4.17). The promyelocytic leukemia (PML) nuclear bodies (sometimes refered to as 
ND-10) were previously shown not to associate with the replication compartment of AAV; 
and to restrict second-strand DNA synthesis [201][202]. 
Next, the question of the effect of SPOP rescue was evaluated. The restoration of SPOP did 
not fully reverse effect on the stability of unassembled capsid proteins (Figure 4.13). The 
protein levels in the rescue cells was generally lower than those seen in the knockout cells, 
but was not able to reach base-line levels seen in the parental cells. Although the restoration 
of SPOP was confirmed through the reappearance of a protein at 42kDa (via western blot), 
there was no guarantee that the protein expressed had the same functionality as the wildtype 
SPOP. Therefore, this was tested by checking the levels of other known endogenous SPOP 
substrates in the rescue cell line (SPOP rescue P2A) (Figure 4.14). The substrates displayed 
different phenotypes: from reducing to levels even lower than those seen in the parental cells 
(DAXX and c-myc), displaying no change (SRC3) and even increasing to levels higher than 
seen in the knockout cells (BRD4). According to the SPOP western blot analysis, the amount 
in the rescue cell lines was 2-fold more than in the parental cell lines. However, the 
overexpression of SPOP was previously shown to promote the degradation of all four 
proteins [148], [195], [197], [203]. Altogether, these variable results were not able to give a 
clear indication of the functionality of restored SPOP. However, this could also be linked to 
differences in cell-type-specific expression of the various proteins, as previously discussed. 
The lack of effect of cullin on newly synthesized capids is in line with the same phenotype on 
incoming capsids (Figure 4.5 and 4.18). Given the numerous BTB proteins within a cell that 
can interact with cullin 3, it is possible that the phenotype observed here is a result of the off-
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target effects by the lack of CRL3 formation with a different protein [137]. Interestingly, in 
this experiment the overexpression of SPOP in the Cul3-downregulated cell lines caused 
some stabilization of VP3. This is peculiar given that SPOP needs to form the CRL3 in order 
to perform its ubiquitination function. However, the appearance of baseline VP expression 
without AAP has also been previously observed [204]. 
If SPOP acts by targeting new capsids to the proteasome, it would be expected that either 
proteasome inhibition or a down regulation of SPOP would have the same effect. This is 
observed in this study, PI use was able to stabilize the unnassembled capsid proteins 
expressed from both AAP-lacking-constructs to similar extent as the lack of SPOP (Figure 
4.19 and 4.20). In line with this, there was little to no effect of PI use in the SPOP knockout 
cells. Interestingly, PI use led to the reduction in intact capsids in both cell lines. Taken 
together, these results elude to the need for some level of ubiquitination in order to stabilize 
the de novo synthesized capsids. Further experiments such as the in vitro ubiquitination 
assays as performed with other SPOP substrates would provide insight into the level/type of 
ubiquitination. 
All in all, this study sheds light on the different roles that players of the E3-ubiquitin ligase 
complex with SPOP and the proteasome plays on various parts of the AAV2 life cycle. Indeed 
if the SPOP binding motifs were purely detrimental to the virus, it would have evolved to lose 
them. In line with this fact are the results on the interaction with newly-synthesized capsids, 
which elude a possible recruitment of the host cell SPOP-CRL3 machinery by AAV to its own 
benefit. Follow up studies would be needed to verify the type and consequence of the 
ubiquitination of newly synthesized capsids. 
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 5.4 Future perspectives 
In order to zero in on the AAV capsid sequences that bind to SPOP, immunoprecipitations 
with the different sections of the VP could be carried out. This assay would verify if the capsid 
sequences are able to bind to SPOP via different sections are in line with co-localization 
experiments. Thereafter, a mutational analysis could be carried out on the putative SPOP 
binding sites to pinpoint if they modulate this interaction. In order to confirm the effect of 
SPOP on transduction, either an overexpression of SPOP in (early passage) knockout cells or 
a transduction assay could be done comparing the knockouts to the SPOP recovery cells. If 
the 2-fold effect is negated upon recovery, this would affirm the role of SPOP on transduction. 
Another option would be to use a cell line that is less permissive to AAV, downregulate SPOP 
and observe if there is an increase in the AAV transduction efficiency. 
 
In terms of understanding the exact mechanisms in which SPOP regulates the stability of 
incoming capsids, it would be imperative to pull down the incoming capsids in the parental 
and SPOP knockout cell lines and probe their ubiquitination status. In vitro ubiquitination 
assays on newly synthesized capsid proteins and assembled capsids with SPOP and several 
SPOP binding mutants and/or capsid mutants would be able to provide more information on 
the type of ubiquitination SPOP facilitates on newly synthesized AAV variants. 
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φ Non-Polar Amino Acid 
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AAV Serotypes 
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CO2  Carbon Dioxide  
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N- Amino-Terminus 
nm  Nanometre  
Na2HPO4  Disodium Hydrogen Phosphate  
NaCl  Sodium Chloride  
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PML  Promyelocytic Leukemia Protein  
POZ Poxvirus and Zinc Finger Domain 
PPi Inorganic Pyrophosphate 
pTAV 2.0 Vector encoding the AAV2 WT Genome 
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pTAVORF2stopB Vector encoding the AAV2 With a STOP In AAP 
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PTM Post Translational Modification 
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RBR RING-Between-RING  
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RPE  Retinal Pigment Epithelium 
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RLU  Relative Light Units  
RNA  Ribonucleic Acid  
RNAi  RNA Interference  
rpm  Revolutions Per Minute  
RT  Room Temperature  
Sae2  SUMO-Activating Enzyme E1 Subunit 2 
SBC SPOP Binding Consensus 
SBS SPOP Binding Site  
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SDS  Sodium Dodecyl Sulfate  
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SRS Substrate Recognition Subunit 
ssDNA  Single-Stranded DNA 
SUMO  Small Ubiquitin-like Modifier  
TAE  Tris-Acetate-EDTA  
TAP Tandem-Affinity Purification 
TE  Tris EDTA  
TEMED  N,N,N’,N’-Tetramethylethylendiamin  
TGS  Tris-Glycine-SDS  
Thr Threonine 
TRAF6 Tumour Necrosis Factor Receptor Associated Factor 6  
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tracrRNA Trans-Acting CRISPR RNA 
Tris  Tris (Hydroxymethyl)-Aminomethan  
trs Terminal Resolution Site 
U  Unit  
UPS Ubiquitin-Proteasome System 
V  Volt  
VEGFR Vascular Endothelial Cell Growth Factor Receptor   
VP  Virus Protein  
VP1  Viral Capsid Protein 1  
VP1u VP1 Unique N-Terminus 
VP2  Viral Capsid Protein 2  
VP3  Viral Capsid Protein 3  
Y2H Yeast-2-Hybrid 
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